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Bone homeostasis is essential for health and is altered in many pathological conditions. A
balance in the activity of osteoblasts (bone-building cells) and osteoclasts (boneresorbing cells) determines the state of bone metabolism, and a tip in this balance toward
either cell type is detrimental to health. In clinical settings, the most common bone
diseases favor increased osteoclast activity and include osteoporosis and rheumatoid
arthritis. Heightened osteoclast differentiation and activation in these conditions causes
bone loss which results in increased fracture risk, bone pain, and deformity.
Understanding the mechanisms by which osteoclasts develop will elucidate important
targets for therapy in these conditions. Osteoclasts differentiate from monocyte
precursors when stimulated by the Ligand for Receptor Activator of NF-κB (RANKL).
Recent research has identified many transcription factors that are activated by RANKL
ii

and are important for osteoclast differentiation. One such family of transcription factors
is NF-κB. We hypothesized that activators of NF-κB are necessary for RANKL-induced
osteoclast differentiation. The Inhibitory kappaB Kinase (IKK) Complex, which consists
of two catalytically active subunits, IKKα and IKKβ, and one regulatory subunit, NEMO,
is the main stimulator of NF-κB downstream of RANK in osteoclast progenitors. Our lab
and others show that this activation is critical for stimulation of NF-κB and
osteoclastogenesis. We sought to further characterize the role of the IKK complex in
osteoclastogenesis by conditionally deleting IKKβ from osteoclast precursors. Using this
mouse model, we demonstrated that IKKβ is critical for differentiation of osteoclasts in
vivo and in vitro, and that IKKβ supports osteoclastogenesis at the levels of
differentiation and survival.

Our model provided a useful tool to study the structural

components of IKKβ which are important for its function in osteoclast differentiation.
Retroviral rescue experiments in which IKKβ KO monocytes were reconstituted with
mutant forms of IKKβ revealed that activation loop serines are critical for IKKβ to
support osteoclast differentiation. These experiments led to the discovery that constitutive
activation of IKKβ results in spontaneous, RANK-independent osteoclast differentiation
in vitro and osteolysis in vivo. Our work demonstrates that IKKβ is central to osteoclast
differentiation and is therefore an important target in therapy for osteoclast-mediated
disease.
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CHAPTER 1
INTRODUCTION

1

RATIONALE AND OBJECTIVE OF THESIS

Arthritis is a medical condition defined as inflammation of the joints and surrounding
connective tissue. Currently, it is estimated that over 46 million Americans suffer from
arthritis, and in 2003, total direct and indirect costs attributable to the condition were
approximately $128 billion 1. Arthritis and its medical complications represent the
leading cause of disability in the United States, and it has been projected that by the year
2020, more than 60 million Americans will suffer from the condition 2. For this reason, it
has been a priority of basic science research to understand the mechanisms underlying the
onset and progression of arthritis and its complications in order to direct and guide
implementation of preventative and therapeutic strategies.

The most devastating complication of arthritis is the destruction of bone associated with
inflammation of joints (osteolysis) which results in pain, deformity, and immobility.
Osteolysis in arthritis is triggered by inflammatory mediators and accomplished by
osteoclasts, cells that resorb bone 3. The discovery that osteoclasts are required for bone
destruction associated with inflammatory conditions

4,5

has led to an intense effort to

characterize the cell and the mechanisms involved in its differentiation and activity.
Indeed, drugs targeting the osteoclast have been demonstrated to improve arthritisassociated osteolysis and are now being considered in the therapy for osteolytic
conditions 6.

2

The objective of this thesis is to investigate the molecular mechanisms utilized by the
osteoclast focusing on the NF-κB pathway (see Background) as a means to better
understand the process of osteoclast differentiation and to offer insight that will guide
therapy of pathological conditions in which the osteoclast is the culprit.

BACKGROUND

Arthritis and the Osteoclast
Arthritis is the leading cause of disability in the United States. Bone-loss associated with
certain types of arthritis is a well-recognized relationship 7,8 and contributes greatly to the
joint pain, deformation, and immobility which often accompanies arthritis. The discovery
of bone-resorbing osteoclasts in arthritic joint tissue led to the hypothesis that osteoclasts
are the culprits in arthritic osteolysis 9. Since this discovery, genetic studies in mice have
confirmed that inflammatory cytokines present in inflamed joint tissue contribute to the
hyperactivation of osteoclasts in this setting 5,10,11, and therapy targeting the osteoclast in
patients with rheumatoid arthritis reduces the osteolysis associated with their condition 6.
It is therefore critical to gain a deeper understanding of the osteoclast and the molecular
mechanisms it utilizes to differentiate and become active in order to more effectively
treat arthritis-associated osteolysis.

3

Osteoclast Biology
The osteoclast is a multinucleated bone-resorbing cell which differentiates from
monocyte precursors under the control of stimulation by two cytokines, Macrophage
Colony Stimulating Factor (M-CSF)
(RANKL)

13

12

and Ligand for the Receptor Activator of NF-κB

. Mice devoid of either cytokine suffer from severe osteopetrosis owing to

failure of osteoclast differentiation, which has become a well-established phenotype in
animals that possess genetic defects in osteoclast differentiation and activity

14

. The

identification of genes whose dysfunction results in osteopetrosis has contributed
tremendously to the understanding of the osteoclast.

The mature osteoclast forms through stimulation of monocytes with M-CSF and RANKL
which triggers a differentiation program leading to fusion of precursors, attachment to
bone matrix, release of protons and proteases, and degradation of bone material

14

.

Inhibition of each of these parameters involved in formation and function of osteoclasts
results in impairment of osteoclast activity. For example, mice devoid of the d2 subunit
of the v0 v-ATPase

15

or DC-STAMP 16, which are critical in osteoclast precursor fusion

display impaired osteoclast activity and increased bone mass. Deficiency in β3-Integrin
results in an osteoclast which is unable to attach effectively to bone, and therefore is
ineffective in resorbing bone substrate 17. Further, mice with a deficiency in Cathepsin K
(Cath K), a protease released by active osteoclasts demonstrate high bone mass

18

.

Moreover, failure to acidify secretory vesicles in osteoclasts results in inefficient bone
resorption

19

(Figure 1). Identification of additional proteins which contribute to the

4

functions of osteoclasts will likely yield a more complete understanding of osteoclast
biology.

Differentiation of the mature osteoclast from monocyte precursors involves integration of
complex signaling cascades activated by RANKL, through TRAF6
and p38 MAP Kinases

22

, PI3K

23

, Akt

24

, c-Src

25

, PKC

26

20,21

, including ERK

, and JNK

27

(Figure 2).

Cooperation of these signals leads to a hierarchy of transcriptional regulation that results
in osteoclast differentiation from precursors. Research has identified several transcription
factors, such as NF-κB

28

, AP-1

27,29

, and NFATc1

30

whose deficiency results in

impaired differentiation of osteoclasts from monocyte progenitors. It is now believed that
the interplay between these transcription factors is critical for osteoclast differentiation 31.

The most important transcription factor for the differentiation of the osteoclast is NF-κB.
NF-κB is activated by RANKL, and several murine genetic models have demonstrated
that NF-κB signaling defects result in impaired differentiation

28,32-39

. Furthermore, NF-

κB appears to be the most upstream transcriptional regulator involved in osteoclast
differentiation

31

. Therefore, understanding NF-κB signaling in the context of osteoclast

differentiation will likely contribute to new therapeutic approaches in the treatment of
osteoclast mediated disease.

5

NF-κB Signaling
NF-κB is a transcription factor activated primarily through receptor stimulation by
extracellular ligands. NF-κB signaling is divided for convenience into two separate
40

which have both

32,33

. In the classical

pathways, classical (or canonical) and non-canonical (alternative)
recently been shown to play a role in osteoclast differentiation

pathway, signals such as RANKL, TNF-α, IL-1, and LPS result in activation of the
Inhibitory κB Kinase (IKK) complex, the catalytic complex which is responsible for
activation of NF-κB. The classical IKK complex consists of two kinases, IKKα and
IKKβ, and a regulatory subunit, NEMO (or IKKγ). Once activated, IKK phosphorylates
IκBα 41, which normally sequesters the NF-κB heterodimers p50/p65 in the cytosol in an
inactive state. Phosphorylation of IκBα results in its ubiquitination and proteasomal
degradation

42

, which releases p50/p65(RelA) NF-κB heterodimers in the nucleus to

activate gene transcription (Figure 3). In the alternative NF-κB pathway 43, extracellular
signals such as RANKL, CD40L, and Lymphotoxin β stimulate activation of IKKα
homodimers which phosphorylate the C-terminus of NF-κB2(p100) which serves an IκB
function for RelB, holding it inactive in the cytosol. This phosphorylation results in
proteasomal processing of p100 to p52, which partners with RelB to enter the nucleus
and activate gene transcription as the alternative NF-κB pathway heterodimer (Figure 4).

Efforts to define the relative contribution of each of these pathways to osteoclastogenesis
have led to disparate conclusions. For example, mice devoid of active IKKα and
alternative NF-κB activation by RANKL demonstrate no apparent bone phenotype and

6

are susceptible to inflammatory osteolysis

37

. However, mice lacking RelB, the

transactivating NF-κB member of the alternative pathway, show impaired osteoclast
differentiation in vitro, and are resistant to pathological bone destruction induced by
tumor metastasis and TNF injection 32. The reason for this discrepancy most likely rests
in the individual systems used to challenge the osteoclast. Nevertheless, it is well
accepted that the classical NF-κB pathway is indispensable for osteoclast differentiation,
since deficiency of IKKβ or RelA results in impaired osteoclastogenesis and
inflammatory osteolysis

33,37,38

. Therefore investigation of classical NF-κB signaling

downstream of RANKL will yield valuable insight into the basic mechanisms utilized by
differentiating osteoclasts.

The Kinase IKKβ
IKKβ is the kinase responsible for activation of the classical NF-κB signaling pathway
43,44

. It is a 756-amino acid cytosolic serine kinase with three general domains, a kinase

domain important for catalytic activity, a leucine zipper domain which is important for
protein-protein interactions, and a helix-loop-helix domain which regulates the
molecule’s kinase activity

45

. Activation of IKKβ requires its association with NEMO

through two Tryptophan residues (739 and 741) located in a caryoxyl terminal domain
termed the NEMO-binding Domain (NBD)

46,47

. Phosphorylation of two activation loop

Serines (177 and 181) on IKKβ by an unknown kinase results in full activation of IKKβ
48

which phosphorylates IκBα leading to NF-κB activation. Pharmacologic inhibition of

IKKβ association with NEMO through the use of decoy peptides blocks activation of NF-

7

κB, inhibits osteoclastogenesis, and prevents arthritis and associated bone loss in mice
35,36

. Phosphomimmetic mutation of IKKβ by mutating Serines 177 and 181 to Glutamic

Acid results in constitutive activation, and mutation of Lysine 44 of IKKβ abrogates
kinase activity 49 (Figure 5).

IKKβ in the Osteoclast
In order to determine the precise role of IKKβ in osteoclastogenesis, we created a mouse
with a conditional deletion of IKKβ in osteoclast precursors by breeding mice possessing
a loxP-flanked IKKβ gene

50

and mice transgenically expressing Cre recombinase under

the control of the CD11b promoter 51. Conditional IKKβ knockout mice generated in this
manner displayed many phenotypic anomalies including aberrant bone metabolism as a
result of defective osteoclastogenesis (Figure 6). The primary goal of this thesis was to
characterize the osteoclast phenotype of these mice, to use the model to study the
structure function relationship of IKKβ in the differentiating osteoclast, and to draw
conclusions regarding the importance of IKKβ in arthritic osteolysis.
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FIGURE LEGENDS

Figure 1: Schematic of Osteoclast Differentiation
Osteoclasts differentiate from monocyte precursors when stimulated by M-CSF and
RANKL, two cytokines secreted by osteoblast cells in normal bone metabolism.
Stimulation of the receptors, c-fms and RANK, by M-CSF and RANKL, respectively,
triggers the activation of the transcription factors, NF-κB, AP-1, and NFATc1 in the
differentiating pre-osteoclast. These transcription factors coordinate the osteoclast
differentiation program resulting in expression of proteins necessary for fusion of
precursors (DC-STAMP), for bone attachment (β3-Interin), for cytoskeletal organization
(c-Src), and for degradation of bone matrix (Cathepsin K and MMP9). Calcitonin
Receptor and Tartrate-Resistant Acid Phosphatase (TRAP) are useful biomarkers for the
mature osteoclast.

Figure 2: Osteoclastogenic Signaling
Stimulation of the receptor, RANK, by its ligand, RANKL, leads to activation of several
kinases including IKK, JNK, ERK, p38, and Akt. These signals require association of the
E3 Ubiquitin Ligase, TRAF6, with the RANK receptor. Interference with each of these
kinases, as well as loss of TRAF6, results in impaired osteoclast differentiation. IKK
activates NF-κB which induces the transcription factor, c-fos. NFATc1, considered the
master regulator of osteoclastogenesis, is activated downstream of NF-κB and AP-1.

16

Figure 3: Classical NF-κB Signaling Pathway
The Classical NF-κB heterodimer, p50/p65(RelA), is bound in an inactive state in the
cytosol by IκBα. Extracellular Signals lead to activation of the classical IKK complex
consisting of IKKα, IKKβ, and IKKγ (NEMO). IKKβ phosphorylates IκBα leading to its
ubiquitylation and rapid degradation by the proteasome. As a result, P50/p65 (RelA)
heterodimers translocate into the nucleus to activate gene transcription.

Figure 4: Alternative NF-κB Signaling Pathway
RelB, the transactivating factor of the alternative pathway, is sequestered in the cytosol
by NF-κB p100. Extracellular signals result in activation of IKKα homodimers. IKKα
phosphorylates p100 resulting in its proteasomal processing to p52. p52/RelB
heterodimers then translocate into the nucleus to regulate gene transcription.

Figure 5: Schematic Structure of IKKβ
IKKβ consists of an N-terminal kinase domain (Kinase) which transfers phosphate from
ATP to target serine and Threonine residues of substrate proteins, a Leucine Zipper
domain (LZ) important for protein-protein interactions, a Helix-Loop-Helix domain
(HLH) which modulates IKKβ kinase activity, and a C-terminal domain (NBD) that is
critical for binding to NEMO. Binding of IKKβ to NEMO, through Tryptophan residues
739 and 741, results in phosphorylation by an upstream kinase of Serines 177 and 181 in
the activation loop in the kinase domain of IKKβ, leading to activation of IKKβ. Lysine
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44 is the ATP-binding residue in IKKβ, and its mutation results in a kinase-inactive,
dominant-negative molecule.

Figure 6: Generation of Mice with a Conditional Deletion of IKKβ in Osteoclast
Precursors
We generated mice with a conditional loss of IKKβ in osteoclast precursors
(OCPΔIKKβ) by crossing mice possessing loxP-flanked (floxed) IKKβ with mice
harboring a Cre recombinase transgene under the control of the CD11b promoter.
Resultant knockout mice (OCPΔIKKβ) displayed dense femurs (arrows) on X-ray
compared with control littermates suggesting that IKKβ is critical for osteoclast
differentiation from precursors.
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CHAPTER 2
DEFECTIVE OSTEOCLASTOGENESIS BY IKKβ-NULL PRECURSORS IS A
RESULT OF RANKL-INDUCED JNK-DEPENDENT APOPTOSIS AND
IMPAIRED DIFFERENTIATION

This chapter is published: Otero J, et al. J Biol Chem. 2008 Sep 5;283(36):24546-53.
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It has previously been reported that IKKβ supports osteoclastogenesis
through NF-B-mediated prevention of apoptosis. This finding suggests that the
ligand for Receptor Activator of NF-B (RANKL), the master osteoclastogenic
cytokine, induces apoptosis of osteoclast precursors (OCP’s) in the absence of
IKKβ/NF-B competency. To validate this hypothesis, we sought to determine the
pro-apoptotic signaling factors induced by RANKL in IKKβ-null osteoclast OCP’s
and to rescue osteoclast differentiation in the absence of IKKβ through their
inhibition. To accomplish this, we generated mice which lack IKKβ in multiple
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hematopoietic lineages including OCP’s. We found that these mice possess both in
vitro and in vivo defects in osteoclast generation, in concurrence with previous
reports, and that this defect is a result of susceptibility to RANKL-mediated
apoptosis as a result of gain-of-function of JNK activation. We demonstrate that
differentiation of OCP’s depends on IKKβ since reduced IKKβ mRNA expression
correlates with impaired induction of osteoclast differentiation markers in response
to RANKL stimulation. We further show that fine-tuned inhibition of JNK
activation in theses cells inhibits RANKL-induced apoptosis and restores the ability
of IKKβ-null OCP’s to become mature osteoclasts. Our data highlight the proosteoclastogenic and anti-apoptotic roles of IKKβ in OCP’s and identify a proapoptotic mechanism activated within the RANK signalosome.

INTRODUCTION

Osteoclasts develop from bone marrow macrophage precursors under the control
of two cytokines, Receptor Activator of NF-κB Ligand1 (RANKL) (1) and m-CSF (2).
RANKL induces osteoclast commitment and development by signaling downstream to
several transcription factors, the most important of which is NF-κB (3). NF-κB is a
family of transcription factors whose activity coordinates a major component of the
cellular inflammatory program, and its function is essential for osteoclastogenesis (4,5).
NF-κB signaling involves two distinct but cooperating pathways, one canonical and one
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alternative pathway (6), which has recently been shown to be critical in osteoclast
biology (7).
NF-κB is activated by the inhibitory κB kinase (IKK) complex, which is crucial
for osteoclastogenesis. The IKK complex is composed of two catalytically active
members, IKKα and IKKβ, and a regulatory subunit IKKγ/NEMO. IKKα mediates
activation of the alternative pathway by phosphorylation of NF-κB2/p100 (6), while
IKKβ is important for activation of the canonical pathway through phosphorylation of
IκB (8). The importance of the signaling activity of the IKK complex in osteoclasts is
demonstrated by the defect in osteoclastogenesis noted in mice lacking IKKα (9) or IKKβ
(10). Despite the sequence homology of these two kinases, their relative importance in
osteoclastogenesis is strikingly different. For example, osteoclasts devoid of active IKKα
only demonstrate an in vitro defect in osteoclastogenesis, while the bone phenotype of the
mouse is remarkably normal. On the other hand, mice with an inducible osteoclast
precursor-specific deletion of IKKβ demonstrate both in vitro and in vivo defects in
osteoclastogenesis and are resistant to inflammatory osteolysis (10). Given these findings,
it is evident that investigating the mechanism by which IKK2 supports osteoclastogenesis
will improve our understanding of osteoclast biology and diseases attributable to
overactive osteoclasts.
We and others have shown that diverse methods of IKK blockade arrest
osteoclastogenesis by induction of apoptosis (10-12). We were interested in the proapoptotic signals downstream of RANKL in the absence of IKKβ, and we hypothesized
that inhibition of these signals would be sufficient to rescue the osteoclast defect of cells
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lacking IKKβ. Our findings reveal that loss of IKKβ in osteoclast precursors (OCP’s)
results in a gain-of-function of JNK activation in response to RANKL that results in
apoptosis. Furthermore, fine-tuned inhibition of this gain-of-function in JNK activation is
sufficient to rescue osteoclastogenesis in OCP’s lacking IKKβ. This finding demonstrates
that the necessity of IKKβ for osteoclastogenesis may be evaded by inhibiting the proapoptotic effects of RANKL and designates JNK activation in the osteoclast as a
potential means to induce cell death in OCP’s.

MATERIALS AND METHODS

Reagents- Antibodies against IKKβ, IKKα, NEMO, Actin, JNK, p38, Akt, MKP1,
phospho-c-jun, and c-jun as well as horseradish peroxidase-conjugated secondary
antibodies were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).
Antibodies against phospho-JNK, phospho-p38, phospho-Akt, and PARP were purchased
from Cell Signaling Technologies, Inc. (Danvers, MA). Antibody against MKP5 was
purchased from Abcam (Cambridge, MA). Cytokines were purchased from R&D
Systems (Minneapolis, MN). TAT-TI-JIP was purchased from EMD Biosciences, Inc.
(La Jolla, CA). Enhanced Chemiluminescence kit was purchased from Pierce
Biotechnology, Inc (Rockford, IL). All other chemicals were purchased from Sigma (St.
Louis, MO) unless otherwise indicated.
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Animals- CD11b Cre Y-chromosomal transgenic and floxed IKKβ mice on a C57BL/6
background were reported previously (12, 13). Male Cre+ Floxed IKKβ homozygotes
were generated by crossing the above mice.

Cell Culture- Osteoclast precursors were enriched from bone marrow of 2-3-week-old
mice. Briefly, whole marrow was flushed from long bones into α-MEM and was
centrifuged at 453 rcf. Marrow pellets were resuspended in whole media (α-MEM with
penicillin/streptomycin, 10% heat-inactivated fetal bovine serum) supplemented with 10
ng/mL m-CSF. Cell suspensions were plated onto petri dishes at 37 oC in 5% CO2 for 5
days and then were plated according to experimental conditions.

Osteoclast Formation Assay- Osteoclast precursors were plated in triplicate at a density
of 3.0 x 104 cells in 200 μL whole media supplemented with 10 ng/mL m-CSF and
RANKL in 96-well tissue culture plates. TAT-TI-JIP was added at the time of cell plating
(day 1). TNF-α and LPS were added at day 4 of the assay. Mature osteoclasts form
between day 5 and day 6 of culture, at which point, the cells are fixed and stained for
Tartrate-Resistant Acid Phosphatase (TRAP) to visualize osteoclasts (Leukocyte Acid
Phosphatase Kit, Sigma, St. Louis, MO). TRAP-positive multinucleated cells with 3 or
more nuclei were scored as osteoclasts.

Protein Phosphorylation Assay- Osteoclast precursors were plated onto tissue culture
dishes overnight in whole media supplemented with m-CSF. Cells were then serum
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starved for 4-6 hours and stimulated with the indicated cytokine for a planned time
course. At the allotted time, cells were lysed in cell lysis buffer containing (20 mM Tris
HCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 2.5 mM NaPyrophosphate, 1
mM β-Glycerophosphate, 1% Triton, 1 mM Na3VO4, 1 μg/mL Leupeptin, 1 mM NaF, 1
mM PMSF, and distilled deionized H2O). Protein concentration was measured by
standard BCA assay (Pierce). 10-20 μg of total cell protein was used for Western blot.
See below.

Apoptosis Assay- Osteoclast precursors were plated onto tissue culture dishes overnight
in whole media supplemented with m-CSF. Cells were serum starved for 6 hours and
stimulated with 10 ng/mL RANKL for the indicated time. At the allotted time, cells were
lysed as described above, protein was normalized, and samples were analyzed by
Western blot. See below.

Rescue of Apoptosis- Osteoclast precursors were plated onto tissue culture dishes for 24
hours in whole media supplemented with m-CSF. Four groups of two plates of cells were
plated in this assay. Each group was treated with either sterile PBS, 0.4 μM, 1.0 μM, or
2.0 μM TAT-TI-JIP. Also at the time of plating, one plate from each group was
stimulated with either sterile PBS or 20 ng/mL RANKL. After 24 hours, cells were lysed
as described above, protein was normalized, and samples were analyzed by Western Blot.
See below.
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Osteoclast Differentiation Assay- Osteoclast precursors were plated in whole media
supplemented with m-CSF. Cells were either not stimulated, or were stimulated with 10
ng/mL RANKL for 5 days. Total RNA was isolated from cells using TRIzol reagent
(Invitrogen, Carlsbad, CA) according to the manufacturer’s standard protocol.

Reverse Transcription- 1.0 μg total RNA was subjected to reverse transcription under the
following conditions. 1.0 μg RNA and 1.0 μg random hexamer primer in 10 μL nucleasefree deionized H2O in PCR tubes were heated to 70 oC for 5 minutes, cooled to 42 oC, and
set on ice. The following components were then added at the indicated amounts or
concentrations for a total reaction volume of 20 μL: 1 x RT AMV buffer (Roche, Palo
Alto, CA), 40U RNAseIn (Promega, San Luis Obispo, CA), 1.25 mM dNTP’s, 5 mM
NaPyruvate, 5 U Reverse Transcriptase Enzyme, AMV (Roche). To produce cDNA,
tubes were placed in a thermocycler programmed as follows. 42 oC for 60 minutes, 50 oC
for 10 minutes, 95 oC for 5 minutes, and 4 oC to hold.

Bone Resorption Assay- Bone marrow osteoclast precursors were plated onto BD Biocoat
Osteologic tissue culture slides (BD Biosciences, San Jose, CA) in the presence of 10
ng/ml m-CSF and RANKL with or without 0.4 µM TAT-TI-JIP for the indicated times.
Resorption pits were determined as clear areas in the osteologic matrix. Representative
photographs were taken at 10X magnification.
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Real-Time PCR- Triplicate samples of 4 μL cDNA product (5X diluted), 10 μL Sybr
Green PCR Master Mix (Applied Biosystems, Inc. Foster City, CA), 0.1 μL each of 10
μM forward and reverse primer stocks, and 6 μL nuclease-free deionized H2O were
subjected to real time PCR according to the following program in a 7300 AB Real Time
PCR System: 50 oC for 2 minutes, 95 oC for 10 minutes, (95 oC for 15 seconds, 60 oC for
1 minute) x 40 cycles. Results were analyzed using AB RQ Study Software. Real Time
PCR primers were designed using Primer Express Software (Applied Biosystems, Inc.)
mouse Actin Forward 5’-CTTCTACAATGAGCTGCGTG-3’, mouse Actin Reverse 5’TCATGAGGTAGTCTGTCAGG-3’,

mouse

CGACCATTGTTAGCCACATACG-3’,

TRAP

mouse

Forward

5’-

Reverse

5’-

TRAP

CACATAGCCCACACCGTTCTC-3’,

mouse

Calcitonin

Receptor

Forward

5’-

CAAGAACCTTAGCTGCCAGAG-3’,

mouse

Calcitonin

Receptor

Reverse

5’-

CAAGCACGCGGACAATGTTG-3’,

mouse

CAGGGAGATGCCCATTTCG-3’,

MMP9

mouse

GGGCACCATTTGGAGTTTCCA-3’,

Forward

5’-

MMP9

Reverse

5’-

A20

Forward

5’-

mouse

CAGAAAAAAGTGGTGAAGGTGTGA-3’,

mouse

A20

Reverse

5’-

CCAGGCTCTGACCTCTGTTACA-3’,

mouse

cIAP1

(birc2)

Forward

5’-

GTGATGGTGGCTTGAGATGTTG-3’,

mouse

cIAP1

(birc2)

Reverse

5’-

(birc3)

Forward

5’-

CAAGAACTCACACCTTGGAAACC-3’,
GAAGTGGGCTGCGGTATCA-3’,
GCGCTGTCTTGAACCATGTTC-3’,
GCGGCTGGGACACTTTTG-3’,

mouse

mouse
mouse
mouse
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cIAP2

cIAP2

(birc3)
Bcl-xL

Bcl-xL

Reverse
Forward
Reverse

5’5’5’-

CAGAACCACACCAGCCACAGT-3’,

mouse

CGGATCGTTACTTTTGGAACATG-3’,

XIAP

mouse

CGCCTTCACCTAAAGCATAAAATC-3’,

Forward

5’-

Reverse

5’-

XIAP

mouse

Cathepsin

K
K

Forward

5’-

Reverse

5’-

GGAAGAAGACTCACCAGAAGC-3’,

mouse

Cathepsin

GTCATATAGCCGCCTCCACAG-3’,

mouse

β3

Integrin

Forward

5’-

TTACCCCGTGGACATCTACTA-3’,

mouse

β3

Integrin

Reverse

5’-

AGTCTTCCATCCAGGGCAATA-3’,

mouse

GAPDH

Forward

5’-

CTTCACCACCATGGAGAAGGC-3’,

mouse

GAPDH

Reverse

5’-

GACGGACACATTGGGGGTAG-3’.

Western Blot Assay- Total cell lysates were boiled in the presence of an equal volume of
2X SDS sample buffer consisting of (0.5 M Tris-HCl, pH 6.8, 10% (w/v) SDS, 10%
glycerol, 0.05% (w/v) bromphenol blue, 3% β-Mercaptoethanol, and distilled water) for 5
min and subjected to electrophoresis on 8–10% SDS-PAGE. The proteins were
transferred to nitrocellulose membranes using a semi-dry blotter (Bio-Rad, Hercules, CA)
and incubated in blocking solution (10% skim milk prepared in phosphate-buffered saline
containing 0.05% Tween 20) to reduce nonspecific binding. The membranes were
washed with phosphate-buffered saline/Tween buffer and exposed to primary antibodies
(16 h at 4 oC), washed again four times, and incubated with the respective secondary
horseradish peroxidase-conjugated antibodies (1 h at room temperature). The membranes
were washed extensively (4 X 15 min), and an ECL detection assay was performed
following the manufacturer’s directions.

34

Western Blot Quantification-Where indicated, protein expression was quantified using
Quantity One 1-D Analysis Software, BioRad (Hercules, CA).
Histology- Long bones were collected from mice and fixed in 10% buffered formalin for
24 hours. Bones were then decalcified for 7 days in decalcification buffer consisting of
(14% (w/v) EDTA, H4NOH pH 7.2), dehydrated in graded ethanol (30%-70%), cleared
through xylene, and embedded in paraffin. Paraffin sections were stained histochemically
for TRAP to visualize osteoclasts or immunohistochemically for TdT-mediated dUTP
Nick End Labeling (TUNEL) with the ApopTag Peroxidase In Situ Apoptosis Detection
Kit (Millipore/Chemicon International, Temecula, CA) to detect apoptotic cells.

RESULTS

Mice with an Osteoclast Precursor- IKKDeficiency Demonstrate in vitro and in vivo
Defects in Osteoclastogenesis
IKKβ has been shown to be necessary for osteoclast formation (10). To define the
mechanism through which IKKβ supports osteoclastogenesis, we generated mice with a
deficiency of IKKβ in multiple hematopoietic lineages including OCP’s by crossing
CD11b Cre recombinase transgenic mice (13) with mice possessing floxed IKKβ (14)
(Supplementary Figure 1). In this study, we focus on the osteoclast phenotype, so we will
refer to the resultant knockout (Cre-positive floxed/floxed IKKβ) mice as OCPIKKor
Cre+ f/f. OCPIKKmice possess a hampered ability to generate osteoclasts in vivo as
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evidenced by a significantly reduced number of TRAP-positive osteoclasts compared
with controls observed by histochemical staining for TRAP in long bones (fig. 1A). This
is further supported by lack of IKKβ protein in osteoclast precursors of OCPIKKmice
(fig. 1B). We demonstrate that this defect is cell-autonomous by culturing bone marrowderived OCP’s in the presence of m-CSF and RANKL. OCPIKKcells form significantly
fewer multinucleated osteoclasts (fig. 1C, panel g) compared with Cre-positive IKKβ
wild-type/wild-type (wt/wt) (fig. 1C, panel a) and Cre-positive IKKβ wild-type/floxed
(wt/f) heterozygous littermate controls (fig. 1C, panel d). Furthermore, stimulation with
TNF-α or LPS (fig. 1C, panels h and i) is insufficient to rescue the osteoclast defect of
OCPΔIKKβ cells. Compared with WT cells, Cre-positive IKKβ (wt/f) OCP’s also show
decreased IKKβ protein expression (fig. 1B), but this difference does not result in
impaired osteoclastogenesis (fig. 1C, panels d-f).

OCPIKK are Prone to RANKL-Induced Apoptosis and Display Defective Osteoclast
Differentiation
IKKβ has previously been demonstrated to protect OCP’s from TNF--mediated
apoptosis (10). We sought to determine whether IKKβ-deficient OCP’s are similarly
susceptible to apoptosis in response to RANKL and to test whether the absence of IKKβ
results in defective osteoclast differentiation. To accomplish this, we cultured
OCPIKKand control OCP’s in the presence of m-CSF and RANKL for zero or five days
to induce osteoclast differentiation. We measured by real-time PCR the expression of
several markers for osteoclast differentiation. We observe a significant decrease in the
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expression of m-RNA for the osteoclast markers β3 Integrin (Fig. 2A), Cathepsin K (Fig.
2 B), Calcitonin Receptor (Fig. 2C), Matrix Metalloproteinase 9 (Fig. 2D), and TRAP
(Fig. 2E) in RANKL-stimulated OCPIKKcells compared with controls. This failure to
express osteoclast markers in osteoclastogenic conditions correlates with up to an 81%
reduction in expression of IKKβ mRNA in OCPIKKcells compared with controls (Fig.
2F). Interestingly, in OCPIKKcells that express higher levels of IKKβ mRNA- 63%
reduction compared with control OCP’s- osteoclast marker expression after RANKL
stimulation is not affected, yet they still fail to form multinucleated osteoclasts in in vitro
culture (Supplementary Figure 2). This finding indicates that IKKβ also serves a
differentiation-independent function to support osteoclastogenesis. These observations
lead us to surmise that IKKβ is essential at various stages for differentiation and survival
of RANKL-stimulated OCP’s.
Therefore, we tested whether OCPIKKcells were more susceptible to apoptosis
than control cells. First, we cultured OCPIKKand control OCP’s in the presence of
whole media supplemented with fetal bovine serum and m-CSF to promote survival and
measured by real-time PCR the expression of mRNA for several NF-B-controlled antiapoptotic proteins (15). We note significant reduction in expression of mRNA for A20,
cellular inhibitor of apoptosis 2 (c-IAP2), c-IAP1, Bcl-xL, and X-linked inhibitor of
apoptosis (XIAP) in OCPIKKcompared with control cells (fig. 2G).
To determine whether OCPIKK undergo apoptosis in response to RANKL, we
exposed serum-starved OCPIKKand control OCP’s to RANKL for a time-course of four
hours. We detected the kinetics of poly-ADP Ribose Polymerase (PARP) cleavage by
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Western blot as a molecular signature of apoptosis. We note disappearance of full-length
PARP in OCPIKKcells after 1 hour while in control cells, the integrity of full-length
PARP is preserved over the time-course of RANKL exposure (fig. 2H), which indicates
that RANKL has a pro-apoptotic effect on osteoclast precursors deficient in IKKβ. We
conclude that IKKβ is necessary for osteoclast differentiation and the survival of
osteoclast precursors exposed to RANKL.
In order to determine whether apoptosis of osteoclasts or OCP’s from
OCPIKKmice contributes to the paucity of osteoclasts observed in vivo, we stained
sections of long bones of OCPIKKand control mice immunohistochemically with the
TUNEL method to detect apoptosis. We note a significantly greater number of TUNELpositive peritrabecular nuclei resembling apoptotic osteoclasts and OCP’s in
OCPIKKcompared with control long bones (fig. 3A and B). Based on our data, we
conclude that apoptosis contributes to the osteoclast defect in OCPIKKmice.

OCPIKK Possess a Gain-of-Function in JNK Activation
We were interested in potential pro-apoptotic signals induced by RANKL in
differentiating IKKβ-deficient OCP’s. To address this, we performed a phospho-protein
screen by Western blot analysis in OCPIKKand control OCP’s after stimulation with a
time course of RANKL or TNF-α. We postulated that OCPIKKkinase signaling would
possess a signature which would favor apoptosis. We noted several aberrations in the
pattern of protein phosphorylation in OCPIKKcompared with control cells. Of particular
interest was an increase and prolongation of JNK phosphorylation in response to RANKL
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(fig. 4A and B) and TNF-α (fig. 4A) in OCPIKKcompared with control OCP’s.
Interestingly, p38 (fig. 4A) and Akt (fig. 4B) phosphorylation remain unaffected in the
absence of IKK, suggesting that JNK downregulation is a specific function of IKKβ.
We observe that MAP Kinase Phosphatase 1 (MKP1) protein resynthesis after
degradation and MKP5 protein synthesis are dampened after RANKL stimulation of
OCPIKKcells compared with controls. In particular, MKP1 and MKP5 protein levels
maximize after 30 minutes of RANKL stimulation of control OCP’s (fig. 4C). This time
point correlates with downregulation of JNK phosphorylation after RANKL stimulation
(fig. 4A and B). In OCPIKKcells, JNK phosphorylation is sustained at 30 minutes of
RANKL stimulation (fig. 4A and B), which correlates with the absence of detectable
MKP1 and MKP5 protein at this time point in OCPIKK cells (fig. 4C). Since MKP1 (16)
and MKP5 (17) serve as JNK phosphatases, MKP induction may serve as an IKKβdependent mechanism for JNK downregulation after RANKL stimulation. We postulated
that the gain-of-function of JNK activation may result in apoptosis of OCPIKKcells.

Inhibition of JNK Blocks RANKL-Induced Apoptosis of Osteoclast Precursors and
Rescues Osteoclastogenesis in IKKβ-Deficient Osteoclast Precursors
JNK activation has been linked to RANKL-induced apoptosis of differentiating
osteoclasts (15). We hypothesized that since OCPIKKcells are susceptible to RANKLinduced apoptosis, inhibition of RANKL- mediated JNK activation in these cells would
rescue osteoclastogenesis. We took advantage of a cell-permeable peptide (TAT-TI-JIP)
to specifically inhibit JNK activation (18) after RANKL stimulation. In WT OCP’s,
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TAT-TI-JIP peptides inhibit osteoclastogenesis at concentrations above 1 M (not
shown). This finding is expected given the established importance of c-jun in osteoclast
differentiation (19,20). Surprisingly, TAT-TI-JIP peptides enhance osteoclastogenesis in
WT cells at a concentration of 0.4 M (fig. 5B panel b). We hypothesized that this
concentration of TAT-TI-JIP is sufficient to block the pro-apoptotic action of JNK
without affecting the activity of JNK toward c-jun after RANKL stimulation. Indeed, 0.4
M of TAT-TI-JIP blocks RANKL-induced PARP cleavage without dramatically
altering RANKL-induced phosphorylation of c-jun (fig. 5A). At a concentration of 1 M,
TAT-TI-JIP inhibits RANKL-induced PARP cleavage in OCP’s, but it also inhibits c-jun
phosphorylation (fig. 5A), which explains the inhibitory affect of this concentration on
osteoclastogenesis. These results suggest that JNK serves two distinct functions in
osteoclast differentiation and survival. Since low dose TAT-TI-JIP inhibits apoptosis of
OCP’s induced by RANKL stimulation without affecting c-jun activation, we tested this
concentration for its potential to rescue osteoclastogenesis of OCP’s in the absence of
IKK. Indeed, in the in vitro osteoclastogenesis assay, 0.4 M TAT-TI-JIP peptide
rescues osteoclastogenesis of OCPIKKcells (fig. 5B). For example, OCPIKKcells (fig.
5B, panel c) treated with RANKL produce less than 5% of the number of TRAP-positive
osteoclasts produced by control OCP’s (fig. 5B, panel a). However, TAT-TI-JIP
treatment of OCPIKK cells (fig. 5B, panel d) results in slightly, but statistically not
significant, higher number of TRAP-positive osteoclasts compared with non-TAT-TIJIP-treated controls (fig. 5B, panel a). Importantly, JIP peptide-treated control OCP’s
(fig. 5B panel b) produced more osteoclasts in in vitro culture than JIP peptide-treated
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IKKβ deficient OCP’s (fig. 5B panel d), indicating that OCPΔIKKβ possess defects in
osteoclast differentiation that are independent of JNK-mediated apoptosis.
Finally, we sought to determine whether rescue of osteoclastogenesis in OCPΔIKKβ
through JNK inhibition results in a concomitant rescue of bone resorption. To accomplish
this, we plated WT and OCPΔIKKβ osteoclast precursors on an artificial bone substrate in
osteoclastogenic conditions in the presence and absence of 0.4 µM TAT-TI-JIP.
Resorption pits created by RANKL-treated OCPΔIKKβ cells (fig.6, panel b) were
significantly smaller (22+/-3% resorption area compared with controls) than those created
by control osteoclasts (fig. 6, panel a), indicating that OCPΔIKKβ are defective in resorbing
bone. However, when we treated OCPΔIKKβ cells with TAT-TI-JIP (fig. 6, panel d), we
restored resorption pit size over that noted in WT non-TAT-TI-JIP treated cells (165+/7% of control) (Fig. 6, panel a). Consistent with our in vitro osteoclastogenesis assay data
shown in figure 5, resorption pit size of TAT-TI-JIP-treated WT osteoclasts (fig. 6, panel
c) is two fold larger than that of TAT-TI-JIP-treated OCPΔIKKβ (210+/-14%) indicating
that IKKβ also acts through mechanisms independent of JNK inhibition to support
osteoclastogenesis.

DISCUSSION
In previous studies, we and others have shown that IKK-NF-κB function is necessary for
osteoclastogenesis (4,10,12). The diverse activities of the individual IKK and NF-κB
members suggest that each molecule plays a unique role in the overall program of
osteoclast development. It has been demonstrated that IKKβ protects OCP’s from
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apoptosis in response to TNF-α (10). While this finding is consistent with previous
reports regarding the function of IKKβ in other settings (21), its precise role downstream
of RANK during osteoclastogenesis has remained unclear. The most likely possibility is
that IKKβ serves some capacity in osteoclastogenesis that is dependent upon NF-κB-p65
action. However, the exact function of p65 in the osteoclast remains to be elucidated. It
has been suggested that IKKβ may be important for the survival and differentiation of
OCP’s (10). We show that OCP’s deficient in IKKβ display a defect in osteoclast
differentiation, which is consistent with impaired induction of mRNA for the osteoclast
markers: β3 Integrin, Cathepsin K, Calcitonin Receptor, MMP9, and TRAP after RANKL
stimulation.
We also show that IKKβ-deficient OCP’s are susceptible to apoptosis in response
to RANKL stimulation. Based on our real-time PCR data, this phenomenon is likely to
partially result from impaired NF-κB-mediated transcription of anti-apoptotic genes.
However, the pro-apoptotic function of RANKL in osteoclast precursors has not been
fully described. Importantly, in OCPΔIKKβ cells which expressed higher levels of IKKβ
mRNA, induction of osteoclast differentiation markers was not affected, although
impaired in vitro osteoclastogenesis was still observed (Supplementary Figure 2). We
examined the expression of mRNA for DC-STAMP (22) and ATP6v0d2 (23), two genes
known to be important in osteoclast fusion, in these cells to determine whether a fusion
deficiency was responsible for the defect. Induction of these markers was equivalent to
controls in this population of OCPΔIKKβ cells (data not shown). Although induction of
other unknown osteoclast fusogenic genes may be impaired in RANKL-treated OCPΔIKKβ
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cells, our data suggests that RANKL-induced apoptosis is a major contributor to the
osteoclast defect in these cells.
We hypothesized that the kinase signaling environment downstream of RANK in
OCPΔIKKβ cells would reveal pro-apoptotic signaling changes. Among several observed
signaling aberrations, we noted in particular that JNK displayed a more robust and
prolonged phosphorylation profile after RANKL stimulation in OCP’s which lack IKKβ.
Since JNK activation has been correlated with RANKL-induced apoptosis previously
(15), we postulated that OCPΔIKKβ cells undergo apoptosis as a result of RANKL
mediated JNK activation. Indeed, by inhibiting JNK-dependent apoptosis, we rescued
osteoclastogenesis in OCPΔIKKβ cells.
We believe that OCPΔIKKβ cells undergo RANKL-induced JNK-dependent
apoptosis early after RANKL stimulation, at a stage prior to the mature osteoclast, for
two reasons. First, the number of multinucleated osteoclasts of RANKL-stimulated
OCPΔIKKβ cells never approaches that of controls cells (unpublished observations).
Second, TAT-TI-JIP only rescues the osteoclast defect of OCPΔIKKβ if added to the
culture at the same time as RANKL stimulation (Supplementary Figure 3, panel c). When
treated with TAT-TI-JIP 48 hours after RANKL stimulation, JNK-inhibition does not
fully rescue osteoclastogenesis of OCPΔIKKβ cells (Supplementary Figure 3, panel d).
Whether the absence of IKKβ protein is essential for the gain-of-function of JNK
in response to RANKL is unknown. For example, it is probable that a downstream
effector of IKKβ signaling and not IKKβ itself, is responsible for inhibition of JNK after
RANKL stimulation. In any case, we demonstrate that fine-tuned inhibition of JNK in
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OCPΔIKKβ cells rescues osteoclastogenesis. Our data suggest a model whereby RANKL
stimulation of OCP’s leads to activation and eventual downregulation of JNK through
MAP kinase phosphatase synthesis. In the absence of IKKβ, RANKL-mediated MKP1
and MKP5 synthesis are defective leading to enhancement and prolongation of JNK
phosphorylation and activation resulting in apoptosis. One may postulate that blockade of
JNK-downregulation through inhibition of the JNK phosphatases will result in enhanced
and prolonged RANKL-induced JNK activity that is anti-osteoclastogenic.
The mechanism of JNK-mediated apoptosis in response to RANKL is not well
defined. It has previously been demonstrated that in response to TNF-α in NF-κBdeficient cells, JNK activation leads to caspase-8 - independent cleavage of the proapoptotic protein, bid, resulting in mitochondrial release of smac and apoptosis (24).
Since RANKL stimulation of OCP’s does not result in caspase-8 activation, it is likely
that enhanced JNK activity in the absence of IKKβ directly leads to apoptosis of OCP’s
after RANKL stimulation. Because lower expression of IKKβ in OCPΔIKKβ cells prevents
osteoclast differentiation, it is unlikely that inhibition of JNK-mediated apoptosis will
rescue osteoclastogenesis in the complete absence of IKKβ. Observing the rescuing effect
of a low-dose JNK inhibitor on osteoclastogenesis in OCPΔIKKβ, therefore, requires a
permissive level of IKKβ expression that allows differentiation to occur but does not
inhibit apoptosis. We believe our CD11b Cre-mediated deletion of IKKβ was a
successful tool in this regard.
In addition to MAP kinase phosphatases, several potential connections between
the absence of IKKβ and enhanced JNK activation exist. For example, known target
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genes of NF-κB serve to downregulate JNK activation such as Gadd45β, which
specifically inhibits TNF-α-mediated MKK7 activation of JNK (25). Additionally, XIAP
is a target of NF-κB which downregulates JNK activation in response to TNF-α (26).
Furthermore, A20 has been postulated to play a role in NF-κB-mediated inhibition of
JNK activation by downregulating TRAF2 (27), although this hypothesis has never been
validated. Since OCPΔIKKβ display reduced XIAP and A20 expression, it will be
interesting to test whether these mechanisms of crosstalk between IKKβ and JNK hold
true in RANKL signaling during osteoclastogenesis.
It is important to note that JNK-mediated c-jun activation is required for efficient
osteoclastogenesis (19). c-jun activation leads to a partnership between AP-1 and NFAT1
which induces expression of NFAT2 and differentiation of osteoclasts (20). Therefore,
inhibition of the RANKL-RANK-JNK pathway is a candidate for treatment of
osteoporosis (28). In light of the opposing effects of the two arms of JNK activation in
the osteoclast, it will be critical to sort out the pro and anti-osteoclastogenic means of
RANKL-mediated JNK activation.
Our results highlight the necessity of IKKβ in osteoclastogenesis. We demonstrate
that IKKβ is important for both differentiation and survival of osteoclasts. Given that we
are able to rescue osteoclastogenesis in OCPΔIKKβ cells through inhibition of JNK-induced
apoptosis, we conclude that IKKβ acts, at least partially, through down-modulation of
JNK activity to support cell survival during osteoclastogenesis. Our results, therefore,
suggest that hyperactivation of JNK and inhibition of IKKβ in OCP’s are potential means
to treat osteoclast-mediated disease.
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FIGURE LEGENDS

Figure 1. Mice with IKKβ–deleted osteoclast precursors possess a defect in in vivo and in
vitro osteoclastogenesis. (A) Histochemical TRAP stain at growth plate of femur of
CD11b Cre-positive wt/wt IKKβ and CD11b Cre-positive floxed/floxed IKKβ
(OCPΔIKKβ) mice to visualize osteoclasts. Arrows indicate osteoclasts. (B) Western blot
for indicated proteins in total cell lysates of osteoclast precursors from CD11b Crenegative, CD11b Cre-positive wt/floxed IKKβ, and CD11b Cre-positive floxed/floxed
IKKβ mice. (C and D) Osteoclast precursors from CD11b Cre-positive wt/wt IKKβ,
CD11b Cre-positive wt/floxed IKKβ, and CD11b Cre-positive floxed/floxed IKKβ mice
were cultured in osteoclastogenic conditions. (C) Cells were either not stimulated (a, d,
g), or were further stimulated with 10 ng/ml TNF-α (b, e, h) or 100 ng/ml LPS (c, f, i) on
day 4 of culture. Cells were fixed and histochemically stained for TRAP to visualize
osteoclasts on day 6 of culture. (D) Quantification of C. TRAP-positive multinucleated
cells (MNC’s) with 3 or more nuclei were scored as osteoclasts. Asterisk indicates p <
0.005 for difference between number of TRAP-positive MNC’s in wells represented by d
and g.

Figure 2. OCPΔIKKβ are defective in osteoclast differentiation and demonstrate increased
susceptibility to apoptosis. OCPΔIKKβ and control OCP’s were plated in whole media
supplemented with 10 ng/ml m-CSF. Cells were either not stimulated or were stimulated
with 10 ng/ml RANKL for 5 days to induce osteoclast differentiation. mRNA was
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collected and analyzed by real-time PCR for markers of osteoclast differentiation: (A) β3Integrin, (B) Cathepsin K (Cath K), (C) Calcitonin Receptor (CtR), (D) Matrix
Metalloproteinase 9 (MMP9), and (E) Tartrate-Resistant Acid Phosphatase (TRAP) as
well as (F) IKKβ (IKK2). GAPDH served as the internal standard for cDNA
normalization. Data are presented as relative quantification with WT non-stimulated
levels serving as the reference point (relative expression value of 1). Values represent
mean quantification plus the standard error of the mean. (G) OCPΔIKKβ and control
OCP’s were plated in whole media supplemented with 10 ng/ml m-CSF. mRNA was
collected and analyzed by real-time PCR for the indicated NF-κB-regulated antiapoptotic proteins: A20, cIAP2 (cellular inhibitor of apoptosis 2), cIAP1 (cellular
inhibitor of apoptosis 1), XIAP (X-linked inhibitor of apoptosis), and Bcl-xL. β-Actin
served as the internal standard for cDNA normalization. Data are presented as relative
quantification with control levels serving as the reference point (relative expression value
of 1). Values represent mean quantification plus the standard error of the mean. Data are
representative of three independent experiments. (H) OCPΔIKKβ and control OCP’s were
serum starved and were either not stimulated or were stimulated with 10 ng/ml RANKL
for 15, 30, 45, 60, or 240 minutes. Total cell lysates were analyzed by Western blot for
integrity of full length PARP (f-PARP). β-Actin served as the loading control.

Figure 3. Apoptosis contributes to the in vivo deficiency of osteoclasts in OCPΔIKKβ mice.
(A)

Immunoperoxidase TUNEL stain and hematoxylin counterstain of histological

sections of growth plate of humerus from OCPΔIKKβ and control mice to visualize
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apoptosis of peritrabecular osteoclasts and OCP’s.

Upper images taken at 10X

magnification, and lower images are panels from upper images taken at 40X
magnification. (B) Graph depicting quantification of TUNEL positive peritrabecular
nuclei per 40X field visualized by light microscopy. Arrows indicate apoptotic nuclei.
Asterisk denotes p < 0.001. (C) TRAP stain of sections taken from same paraffin
embedded bones used for TUNEL stain in (A) to demonstrate correlation between
apoptosis and defective in vivo osteoclastogenesis.

Figure 4 . Loss of IKKβ in OCP’s results in a gain-of-function in JNK phosphorylation.
OCPΔIKKβ and control OCP’s were serum starved for 4-6 hours. (A) Cells were either not
stimulated or were stimulated with 10 ng/ml RANKL or TNF-α for 5, 10, or 30 minutes.
(B) Cells were either not stimulated or were stimulated with 10 ng/ml RANKL for 7.5,
15, 30, or 60 minutes. Total cell lysates were then analyzed by Western blot for the
indicated phosphorylated proteins and whole proteins. Equal loading for phosphorylated
proteins was determined by stripping the membrane and re-probing for the respective
whole protein (A and B). (C) Cells were stimulated with 10 ng/ml RANKL for 10, 15, 30,
or 120 min. Total cell lysates were then analyzed by Western blot for MKP5 and MKP1.
β-Actin served as the loading control.

Figure

5.

Inhibition

of

RANKL-mediated

JNK-induced

apoptosis

rescues

osteoclastogenesis defect in OCP’s deficient in IKKβ. (A) OCP’s from Cre+ wildtype/floxed IKKβ mice were plated in whole media supplemented with 10 ng/ml m-CSF.
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Four groups of cells were treated at the time of plating with either no TAT-TI-JIP or with
0.4 μM, 1.0 μM, or 2.0 μM TAT-TI-JIP. Also at the time of plating, one sample in each
group was stimulated with 20 ng/ml RANKL. Cells were lysed after 24 hours of
stimulation and total cell lysates were analyzed by Western blot for cleaved PARP (cPARP), phosphorylated c-jun (p-c jun), and total c-jun. Cleaved PARP and phospho-c jun
quantification in the different conditions is shown in numerical and graph form under the
corresponding blot image. (B) OCPΔIKKβ and control OCP’s were plated in
osteoclastogenic conditions. At the time of plating, one group of cells from each
population was either left untreated (a and c) or treated with 0.4 μM TAT-TI-JIP (b and
d). Cells were fixed and histochemically stained for TRAP to visualize osteoclasts on day
6 of culture. Quantification is shown in graph below. TRAP-positive multinucleated cells
(MNC’s) with 3 or more nuclei were scored as osteoclasts. Data are representative of
three independent experiments, and error bars represent standard error of the mean.
Asterisk indicates p < 0.0001 for difference between number of TRAP-positive MNC’s in
wells represented by a and c. No significant difference exists between a and d.

Figure 6. Inhibition of JNK in OCPΔIKKβ cells rescues bone resorption. Control (panels a
and c) and OCPΔIKKβ (panels b and d) osteoclast precursors were plated onto BD Biocoat
Osteologic tissue culture slides in osteoclastogenic conditions in the absence (panels a
and b) or presence (panels c and d) of 0.4 µM TAT-TI-JIP. Cells were removed from the
slides with deionized water, and resorption pits were noted as clear areas. Images were
taken at 10X magnification.
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Supplementary Figure 1. Deletion of IKKβ in multiple hematopoietic tissues. Southern
blot for IKKβ gene from DNA of bone, thymus (thym), and spleen of CD11b Cre +
floxed/floxed IKKβ mice. Floxed; loxP-flanked, Δ; deleted by Cre.

Supplementary Figure 2. OCPΔIKKβ with insufficient suppression of IKKβ mRNA show
defective osteoclast phenotype in vitro despite normal induction of osteoclast markers.
Control and OCPΔIKKβ osteoclast precursors were either not treated (unstim) or were
treated with RANKL for 5 days. At day 5, mRNA was collected from cells for analysis of
gene expression for (A) β3-Integrin, (B) TRAP, (C) Calcitonin Receptor, and (D) IKKβ.
RANKL-treated cells were also TRAP-stained (E) for visualization of osteoclasts.

Supplementary Figure 3. Requirement for early inhibition of JNK for rescue of
osteoclastogenesis in OCPΔIKKβ. Control (a) and OCPΔIKKβ (b-d) osteoclast precursors
were treated with RANKL for 5 days. For JNK inhibition, OCPΔIKKβ cells were either not
treated (b) or were treated with 0.4 µM TAT-TI-JIP at the same time as the first RANKL
stimulation (c) or 48 hours later (d).
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SUMMARY:
Osteoclasts differentiate from monocytes through stimulation of Receptor-Activator of
NF-κB (RANK). Many downstream effectors of RANK play a positive role in
osteoclastogenesis, but their relative importance in osteoclast differentiation is unclear.
We report the discovery that introduction of constitutively activated IKKβ (IKKβSSEE)
into monocytes stimulates differentiation of bona-fide osteoclasts in the absence of
RANK Ligand (RANKL). This phenomenon is independent of upstream signals, since
IKKβSSEE induced the development of bone-resorbing osteoclasts from RANK and IKKαknockout monocytes and in conditions in which NEMO-IKKβ association was inhibited.

65

NF-κB p100 and p105 -but not RelB- were critical mediators of this effect. More
importantly, adenoviral gene transfer of IKKβSSEE induced osteoclasts and osteolysis in
calvariae and knees of mice. Our data establish the sufficiency of IKKβ activation for
osteolysis and suggest that IKKβ gain-of-function may be a causative factor in conditions
of pathological bone destruction refractory to RANK/RANKL proximal therapeutic
interventions.

INTRODUCTION:
Healthy bone balance is dependent on the concerted activity of osteoblasts, bone
forming cells, and osteoclasts, bone resorbing cells. In pathological conditions such as
rheumatoid arthritis, osteoporosis, and osteolytic cancer metastasis, bone balance tips in
favor of increased osteoclast activity, stemming from heightened osteoclast
differentiation and activation1. These conditions result in significant bone pain and
increased risk of fracture. Therefore, therapies which target the osteoclast are in the
armament for treatment of these conditions2. On the other hand, gene mutations that
disrupt osteoclast differentiation lead to development of osteopetrotic dense bones
compromising bone homeostasis3. This class of bone diseases is incurable owing to
osteoclast deficiency and lack of bone resorption. Undoubtedly, increasing understanding
of the factors which regulate the osteoclast in health and disease will offer important
insight into new effective therapies for bone loss associated with pathological conditions
and for osteopetrosis.
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The osteoclast is the sole bone resorbing cell, and it differentiates from a
monocyte precursor through the concerted action of two cytokines, Ligand for the
Receptor Activator for NF-κB (RANKL) and Macrophage Colony Stimulating Factor
(M-CSF)1. Upon stimulation of their cognate receptors, RANK and c-Fms respectively, a
series of signaling events induces activation of transcription factors such as NF-κB, AP-1,
and NFATc1 which results in fusion of precursors and expression of genes required for
osteoclast function, including β3-Integrin, Cathepsin K, Tartrate Resistant Acid
Phosphatase (TRAP), and Matrix Metalloproteinase 9 (MMP9)4. With expression of all
necessary genes for osteoclast differentiation, the ability of the osteoclast to resorb bone
requires tight regulation of the actin cytoskeleton. Indeed, genetic murine models have
revealed a number of proteins such as c-Src5, β3-Integrin6, ITAM containing adaptors7,8,
and the small GTPase Rac9 whose activity is required for cytoskeletal regulation and
bone resorption. These molecules contribute to formation of the actin ring which is the
signature of a polarized osteoclast capable of resorbing bone10.
The complement of proteins whose expression and activation are important for
osteoclast differentiation and function make up a growing list, but the relative importance
of these genes remains unclear given the varied phenotypes of osteoclasts or osteoclast
precursors devoid of any of them. A well-studied family of transcription factors which is
required for osteoclastogenesis is NF-κB. Recent findings have revealed that NF-κB p100
and p105 are both required together for osteoclast differentiation11. Additionally,
p65/RelA12 and RelB13 have been shown to play complementary roles in osteoclast
survival and differentiation, respectively. The complex interplay between NF-κB family
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members in the context of osteoclast differentiation remains to be worked out, but it is
clear that factors which activate NF-κB are logical targets for the treatment of osteoclastmediated disease.
The IκB Kinase (IKK) Complex is responsible for NF-κB activation downstream
of RANK. Upstream signals lead to association of two catalytically active kinases, IKKα
and IKKβ with the non-catalytic member, IKKγ/NEMO. This association is required for
activation of IKK through phosphorylation of two IKK activation loop serines, via an
unidentified upstream kinase. IKK then phosphorylates IκB targeting it for proteasomal
degradation allowing NF-κB to enter the nucleus and regulate gene transcription14-16. We
and others have shown that inhibition of IKK activation through pharmacological
inhibition of IKK association with NEMO abrogates osteoclastogenesis and
inflammatory osteolysis17,18. Furthermore, mice devoid of IKKα19 or IKKβ20,21
demonstrate an impaired ability for osteoclast development in vitro. In a study comparing
the relative contributions of the catalytic IKK members to osteoclast development in vivo,
mice devoid of IKKβ displayed osteopetrosis and resistance to inflammatory bone
erosion, while mice lacking active IKKα showed no obvious skeletal phenotype20. This
finding implicates IKKβ as an important target for therapy in osteoclast-mediated disease.
We now report that IKKβ is not only necessary for RANKL-mediated
osteoclastogenesis, but its activation is sufficient for RANK-independent osteoclast
formation. Using retroviral delivery of constitutively active IKKβ (IKKβSSEE), we reveal
a signal for differentiation of functional osteoclasts that occurs downstream of RANK.
IKKβSSEE-but not wild-type IKKβ nor IKKαSSEE-induces osteoclast differentiation from
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bone marrow, spleen, and fetal liver monocytes. These osteoclasts express all markers for
normal osteoclasts, they form actin rings, and they resorb bone demonstrating that they
are indeed authentic osteoclasts. Importantly, RANK is not a requirement since IKKβSSEE
induces formation of bone resorbing osteoclasts from RANK-null spleen monocytes.
Furthermore, we show that the classical IKK complex is not a requirement for active
IKKβ to drive osteoclastogenesis, since IKKβSSEE induces formation of bone-resorbing
osteoclasts from IKKα null fetal liver monocytes and when NEMO binding is inhibited.
Finally, adenoviral gene transfer of IKKβSSEE in knees and calvariae of mice is sufficient
for development of massive osteolysis. In summary, our findings demonstrate for the first
time that a single activated kinase is sufficient for RANK-independent osteoclast
differentiation and that active IKKβ alone leads to the development of osteolytic disease.
These data highlight the centrality of IKKβ in osteoclast differentiation and implicate
gain-of-function of IKKβ in pathological bone destruction.

RESULTS:
Constitutively

Active

IKKβ

Induces

RANKL-Independent

Osteoclast

Differentiation from Monocytes
Recently, we and others have demonstrated the necessity for IKKβ in osteoclast
differentiation

20,21

. In an effort to identify mutations in IKKβ which could prevent or

enhance its ability to rescue osteoclast differentiation in IKKβ knockout (KO) osteoclast
precursors, we made the surprising observation that introduction of the constitutively
activated form of IKKβ (IKKβSSEE), but not the wild-type (IKKβWT) form, into wild-type
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or IKKβ KO bone marrow-derived macrophages induced the formation of TRAP-positive
osteoclasts in the absence of RANKL administration (Fig. 1A, and Supplementary
Figures 1 and 2). These cells were morphologically indistinguishable from RANKLinduced osteoclasts. Levels of IKKβWT and IKKβSSEE protein were comparable (Fig. 1B),
whereas IKKβSSEE but not IKKβWT was recognized by an antibody specific for IKKβ
phosphorylated at activation loop serines (Fig. 1C). These observations suggest that the
kinase domain of IKKβSSEE exists in an active conformation and further assert that
mutation of IKKβ activation loop serines 177 and 181 to glutamic acid, and not
overexpression of IKKβ per se, is the factor responsible for the formation of osteoclasts
in the absence of RANKL.
Further characterization showed that IKKβSSEE, but not GFP or IKKβWT, induced
expression of RelB and c-fos, two transcription factors known to be critical for normal
osteoclast differentiation13,22. IKKβSSEE but not IKKβWT, also induced the expression of
β3-Integrin and Cathepsin K, two markers for mature osteoclasts and genes whose
products are required for osteoclast bone resorption6, 23, (Fig. 1C). Quantitative real-time
PCR analysis revealed that IKKβSSEE induced expression of mRNA for calcitonin
receptor, cathepsin K, TRAP, and β3-integrin, indicating that these cells possess the
molecular signature for true osteoclasts (Fig. 1D). This notion was further supported by
experiments showing that, similar to RANKL-induced cells, osteoclasts derived through
introduction of IKKβSSEE into precursors form actin rings and are capable of resorbing
artificial (Supplementary Figure 3) and authentic bone matrix (Fig. 1E). Expression of
IKKβSSEE by RANKL-independent osteoclasts was demonstrated using IKKβSSEE-GFP
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fusion construct (Fig. 1F). These data provide evidence that the TRAP+ multinucleated
cells induced through expression of constitutively active IKKβ in macrophages are
authentic osteoclasts. Furthermore, the fact that both bone marrow and spleen-derived
macrophages were susceptible to osteoclast induction by IKKβSSEE argued against the
theoretical possibility that IKKβSSEE may induce osteoclastogenesis in a paracrine
fashion.
Given the implications of this finding in studying osteoclast signaling in various
genetic models for osteoclast impairment which result in embryonic lethality, we sought
to examine whether stimulation of osteoclast differentiation through introduction of
IKKβSSEE was a phenomenon restricted to precursors obtained from adult tissue. To this
end, IKKβSSEE– infected but not GFP or IKKβWT– infected fetal liver cells formed
authentic osteoclasts with visible actin rings, a critical step in osteoclast polarization10,
which are capable of resorbing dentin slices (Fig. 1E). Actin rings and resorption pits
were observed in IKKβWT-infected cells only after RANKL administration (Fig. 1E,
Supplementary Figure 4). These observations reveal that IKKβSSEE is sufficient to
induce an authentic program for functional osteoclasts from adult and fetal precursor cells
independent from RANKL. To verify the specificity of the osteoclastogenic effect of the
phosphomimmetic mutation, we mutated IKKβ activation loop Serines to Alanine
(IKKβSSAA). This mutation resulted in an activation deficient molecule which failed to
rescue basal and IL-1-induced osteoclastogenesis in IKKβ KO monocytes (Fig. 1G and
H). This result indicates that phosphomimmetic mutation of IKKβ activation loop Serines
is a specific inducer of the osteoclast program.
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IKKβSSEE Rescues RANK Knockout Osteoclast Phenotype
Having

established

that

RANKL

is

dispensable

for

IKKβSSEE-mediated

osteoclastogenesis, we sought to determine whether intrinsic RANK signaling played a
role in this phenomenon. To accomplish this, the RANKL decoy molecule
osteoprotegerin (OPG-Fc) 10,24 and RANK-null cells were employed. OPG-Fc completely
inhibited RANKL-induced osteoclastogenesis in IKKβWT -infected macrophages but had
absolutely no effect on IKKβSSEE–induced osteoclast differentiation indicating that
IKKβSSEE induces osteoclastogenesis without RANKL (fig. 2A). Furthermore, IKKβSSEE,
but not IKKβWT nor GFP, induced the formation of osteoclasts from RANK knockout
cells (Fig. 2B), excluding the possible necessity for an intrinsic effect of RANK.
Importantly, RANK KO spleen-derived macrophages expressing GFP or IKKβWT failed
to form osteoclasts in response to RANKL (Fig. 2B). IKKβSSEE- induced osteoclasts were
also observed to form actin rings and resorb dentin (Fig. 2C). Consistent with this result,
Western blot revealed that IKKβSSEE introduction into, but not RANKL treatment of,
RANK KO cells resulted in expression of c-fos and RelB as well as c-src, β3-Integrin,
and Cathepsin K (Fig. 2D), indicating that IKKβSSEE-induced RANK-KO osteoclasts are
indeed bona fide osteoclasts which appear molecularly identical to those derived from
RANKL treatment of wild-type precursors. Furthermore, quantitative real-time PCR
revealed that IKKβSSEE induces expression of mRNA for TRAP, Calcitonin Receptor,
Cathepsin K, and β3-Integrin in RANK KO cells (Fig. 2E). These data prove that
IKKβSSEE functions independent of RANK to induce a program for differentiation of
functional osteoclasts.
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IKKβSSEE Acts Independently from the Classical IKK Complex to Drive
Osteoclastogenesis
Activation of IKKβ by upstream signals requires its association, via two carboxylterminal tryptophans (W739 and W741), with the non-catalytic IKK member, NEMO25,
26

. We and others have shown that inhibition of this association blocks RANKL-induced

IKK activity and inhibits osteoclastogenesis and osteolysis17,18. Since IKKβSSEE induces
osteoclastogenesis independent from RANK signaling, we tested if IKKβSSEE could also
induce osteoclastogenesis in the absence of NEMO binding. We employed
pharmacologic and molecular approaches to test this hypothesis. First, we determined
that while administration of cell-permeable NBD peptides, which inhibit the association
of IKKβ with NEMO, blocks RANKL-induced osteoclast differentiation, NBD did not
inhibit osteoclastogenesis in response to transduction of IKKβSSEE (Fig. 3A). Second,
while compound mutations of W739 and W741 to Alanine in the presence of the S177
and S181 to Glutamic Acid (IKKβSSEE/WA) prevent IKKβSSEE from binding to NEMO
(Fig. 3B,C), IKKβSSEE/WA is still capable of inducing RANKL-independent
osteoclastogenesis from bone marrow macrophages to the same degree as IKKβSSEE
(figure 3D). This quadruple IKK mutant is expressed properly and retains its kinase
activity (Fig 3E, F). Collectively, these results solidify the conclusion that IKKβSSEE
induces RANKL-independent osteoclastogenesis without binding to NEMO, uncoupling
the mechanism of IKKβSSEE – induced osteoclastogenesis from virtually all known
upstream stimuli important for osteoclast differentiation and activation. Furthermore, this
result suggests that in the setting of osteoclast differentiation, IKKβ binding to NEMO is
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only important for IKKβ activation loop phosphorylation, after which point the
association is not required for IKKβ to induce osteoclastogenesis.
Since NEMO association was not required for this phenomenon, we hypothesized
that IKKβSSEE could induce osteoclastogenesis without formation of the classical IKK
complex which includes IKKα, a kinase that has been shown required for
osteoclastogenesis in vitro19. First, we confirmed that IKKα-null fetal liver-derived
macrophages (FLC) transduced with GFP do not differentiate into osteoclasts (Fig. 4A)
and fail to express mRNA for the osteoclast markers TRAP, Cathepsin K, and calcitonin
receptor in response to RANKL stimulation while induction of these markers is normal in
littermate control cells treated with RANKL (Fig. 4C). However, transduction of IKKα
knockout FLCs with IKKβSSEE restores osteoclastogenesis even in the absence of
RANKL administration, rescues the ability of these cells to form normal actin rings and
to resorb bone (Fig. 4A), and induces expression of typical signaling proteins (Fig. 4B)
and expression of mRNA for Cathepsin K, TRAP, and Calcitonin Receptor (Fig. 4C).
These data indicate that formation of the classical IKK complex and the IKKα-mediated
non-canonical NF-B signaling pathway are not a requirement for IKKβSSEE to stimulate
RANK-independent osteoclastogenesis.

Requirement

for

Coordinated

NF-κB

Activation

in

IKKβSSEE–Induced

Osteoclastogenesis
In an effort to identify the mechanism underlying IKKβSSEE-induced osteoclastogenesis,
we examined the status of essential NF-B subunits compared with RANKL-treated
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conditions. We observed elevated total levels of RelB in the cytosol of IKKβSSEE –
expressing cells at all time points assessed, including non-stimulated, compared with
GFP and IKKβWT expressing cells. RelB translocation into the nucleus was only slightly
stimulated by RANKL in the time course of one hour. We also observed reduced levels
of IB which coincided with a dramatically increased level of RelA protein in the
nucleus in the absence of RANKL stimulation and at all time points tested in IKKβSSEE
compared with GFP and IKKβWT expressing cells, indicating that the constitutively
activated form of IKKβ induces continuous IκBα processing (Fig. 5A). These data
suggest that IKKβSSEE may act through an NF-κB-dependent mechanism to induce
RANK-independent osteoclast differentiation. To test this hypothesis, we began by
challenging RelB knockout cells with IKKβSSEE, since we repeatedly observed induction
of RelB protein expression in response to IKKβSSEE in macrophages and since a positive
role for RelB in osteoclast differentiation was recently described13. To our surprise, RelB
knockout bone marrow-derived macrophages were capable of differentiating into TRAP+
osteoclasts which express Cathepsin K in the absence of RANKL-administration when
expressing IKKβSSEE but not IKKβWT (Fig. 5B,C). Real-time PCR analysis also revealed
that while induction of expression of mRNA for Calcitonin Receptor and TRAP in
response to RANKL administration was impaired in RelB knockout cells, IKKβSSEE
rescued the induction to levels equivalent to that seen in WT cells expressing IKKβSSEE
(Fig. 5D). These data indicate that IKKβSSEE does not require RelB to induce osteoclast
differentiation.
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Given the observation that IKKβSSEE induces nuclear translocation of RelA and
induces increased expression of RelB, we further explored the possibility that these NFB subunits may act as mediators of the IKKβSSEE effect. However, overexpression of
RelA, RelB, or a combination of RelA and RelB (Fig. 5E) did not induce osteoclast
differentiation of bone marrow-derived macrophages. To verify activity of the RelA and
RelB in this setting, we observed that RelA induced expression of IκBα and that RelA
and RelB as well as the combination of RelA and RelB induced expression of p100. (Fig.
5F).Collectively, these results indicate that IKKβSSEE is a specific activator of NF-κB
capable of inducing osteoclast differentiation and simple ectopic overexpression of RelA
plus RelB is insufficient to coordinate this effect.
Phosphorylation of T-loop residues is a hallmark of activation for many kinases27.
Given the specificity of IKKβ T-loop activation as a mediator of osteoclast
differentiation, we asked whether constitutive activation of other kinases through
phosphomimetic mutations could induce osteoclast differentiation or whether this effect
is specific to IKKβ. IKKα and IKKβ share significant primary and secondary structural
homology15, so we reasoned that, in contrast to other less-related kinases, constitutive
activation of IKKα through phosphomimetic mutation (S176/180E) would be most likely
to induce an osteoclast program like IKKβSSEE.

We found that when expressed at

comparable levels (Fig. 5E), IKKβSSEE induces osteoclast differentiation from bone
marrow macrophages, whereas IKKαSSEE had no such effect (Fig. 5F), demonstrating that
IKKβ is the specific kinase activator of the osteoclast program.
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It has been established that a combination of both NF-κB1/p50 and NF-κB2/p52
subunits are absolutely required for osteoclast differentiation11. We wished to determine
whether IKKβSSEE-induced RANK-independent osteoclastogenesis also requires NF-κB1
and 2. To accomplish this, we transduced control and NF-κB1-/- / NF-κB2-/- (NF-κB
dKO) spleen macrophages with GFP, IKKβWT, and IKKβSSEE (Fig. 5G) and performed
TRAP staining for osteoclasts in the absence of RANKL administration. While control
cells expressing IKKβSSEE produced a significant number of osteoclasts capable of
resorbing bone coinciding with expression of mRNA for Cathepsin K, no osteoclasts
were observed in NF-κB dKO cells (Fig. 5H,I) despite constitutive IκBα processing
(Supplementary Figure 5). These results indicate that IKKβSSEE-mediated induction of
osteoclastogenesis requires NF-κB-mediated gene regulation.

Constitutively Active IKKβ is Sufficient for the Establishment of in vivo Osteolysis
To determine the relevance of active IKKβ to osteoclastogenesis and osteolysis in vivo,
we performed gene transfer experiments in mice. We injected mice with adenovirus
expressing IKKβSSEE or lacZ supracalvarially or intra-articularly into the knee joint
(Supplementary Figure 6). While lacZ did not induce an osteoclast response in either
calvariae or knees, IKKβSSEE stimulated a massive local osteolytic response in both
settings characterized by bone destruction and the appearance of osteoclasts at sites of
bone erosion (Fig. 6A,B). To support the role of kinase activity of IKKβ in mediating this
effect, joints injected with adenoviral IKKβSSEE showed intense immunostaining for
phosphorylated IκBα at sites of synovial inflammation and osteoclastic articular bone
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erosion, while LacZ-infected knees stained negatively for articular osteoclasts and
phosphorylated IκBα (Fig. 6B).

DISCUSSION:
We provide novel evidence that osteoclast differentiation from monocyte
progenitors can be triggered by an autonomous intracellular signal downstream, yet
independent of the RANK receptor. The IKK complex has been implicated in RANKLinduced osteoclast differentiation17-21, but the sufficiency of this single enzyme to
independently induce osteoclastogenesis is surprising. The fact that constitutively
activated IKKβ induces osteoclast differentiation raises several questions. First and
foremost, phosphorylation of IKKβ is not unique to the RANKL/RANK signaling
complex, so why do other receptor signaling complexes which activate IKKβ fail to
induce osteoclast differentiation? The answer to this question, most likely, lies in the
tuning of IKK-mediated NF-κB activation by RANK. It has recently been demonstrated
that at the level of promoter binding and gene activation, the timing of NF-κB oscillations
in concert with AP-1 determines transcriptional output28. These oscillations are
differentially regulated by TNF and RANKL, despite their activation by both cytokines,
resulting in transcription at different promoters. Our data predicts that NF-κB activation
through IKKβ in monocyte progenitors is more sustained and prolonged by RANKL than
other cytokines and that prolonged activation of IKK/NF-κB results in transcription at
osteoclast-specific gene promoters. Second, in light of its osteoclastogenic function, it is
interesting to consider how closely IKKβSSEE mimics the molecule when activated
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through NEMO association-dependent phosphorylation. It is possible that IKKβSSEE takes
on functions not performed by IKKβ in normal settings. In support of this speculation, we
observe that infection of monocytes with IKKβSSEE results in p100 processing to p52,
which is usually considered to be a function of IKKα29. Perhaps atypical functions like
this contribute to its osteoclastogenic activity. Nevertheless, the ability of IKKβSSEE to
induce the osteoclast is entirely dependent on kinase activity, since mutation of the ATPbinding lysine to methionine in the kinase domain completely abrogated the IKKβSSEE
osteoclastogenic function (Supplementary Figure 7). Another explanation of the high
specificity with which active IKKβSSEE prompts osteoclastogenesis in monocytes despite
the fact that this kinase can be activated by numerous stimuli in other systems devoid of
osteoclasts, can be attributed to the fact that upstream ligands prompt complex
stimulatory and inhibitory circuits to modulate their responses. These complex circuits
emanating from ligand/receptor interactions are absent from the IKKβSSEE response,
suggesting that the immediate IKK response is induction of osteoclastogenesis whereas
upstream receptor-based regulatory signals induced by various stimuli, such as TNF,
lipopolysaccharide, IL-1, etc, provide networks that counteract the IKKβSSEE
osteoclastogenic effect.
In addition to IKKβ, several kinases have been demonstrated to play a role in
osteoclast differentiation including ERK and p38 MAP Kinases30, PI3K31, Akt32, c-Src33,
PKC34, and JNK35. Many of these kinases have been demonstrated to be essential to
osteoclastogenesis, but it has been difficult to sort out their individual contributions to
differentiation for two main reasons. First, survival defects mask the effect of null
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mutations on differentiation. Second, no kinase has ever been studied for its sufficiency
to activate the osteoclast program. Our discovery that constitutively activated IKKβ
stimulates osteoclast differentiation led us to question the uniqueness of IKKβ in
accomplishing this function. To address this, we mutated IKKα to create a constitutively
active mutant with significant structural and sequence similarity to IKKβSSEE. This
molecule was insufficient for osteoclastogenesis, which led us to conclude that IKKβ is
uniquely situated to stimulate the osteoclast program. In this regard, it is interesting that
IKKβSSEE did not require IKKα or NEMO, its members in the traditional IKK complex 15.
This observation strongly suggests that the function of IKKα and NEMO in the setting of
osteoclast differentiation is to facilitate activation of IKKβ.
It is important to consider the extent to which IKKβSSEE-induced osteoclasts
resemble those induced by RANKL. With regard to their ability to resorb bone, they are
indeed bone fide osteoclasts. This is supported by the fact that the same transcription
factors which are important for RANKL-induced osteoclast differentiation are also
upregulated by IKKβSSEE, including RelB, c-Fos, and nuclear p65/RelA. Furthermore, our
analysis revealed that IKKβSSEE potently induced expression of markers for RANKLinduced osteoclasts, TRAP, Cathepsin K, Calcitonin Receptor, and β3-Integrin. In
addition to these, preliminary mRNA expression array revealed significant upregulation
of DC-STAMP, OSCAR, as well as MMP9, further validating the IKKβSSEE-induced
osteoclast phenotype.
Differentiation of the osteoclast requires NF-κB11. To determine whether the
phenotype we observed similarly requires NF-κB we tested the ability of IKKβSSEE to
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drive osteoclastogenesis in NF-κB1/2 double knockout spleen monocytes, in which it
failed. In addition to NF-κB, other transcription factors may play a role in the IKKβSSEE
effect. c-Fos has been implicated downstream of NF-κB for osteoclastogenesis, and in the
NF-κB1/2 double knockout, failure of c-Fos upregulation in response to RANKL has
been shown to lead to impaired differentiation36. We saw no defect in c-Fos upregulation
by IKKβSSEE in the NF-κB1/2-null setting meaning that c-Fos induction is not sufficient
for osteoclastogenesis (Unpublished data, J.O. and Y.A.). Therefore, NF-κB must serve
functions other than c-Fos upregulation which are necessary for osteoclast differentiation.
Identification of these targets will lead to a better understanding of NF-κB in the
osteoclast.
Another puzzling question prompted by our data regards the mechanism through
which IKKβSSEE induces formation of the Actin ring. It is known that complicated
signaling at the membrane of osteoclasts associated with integrin stimulation ultimately
results in formation of the actin ring which allows formation of the sealing zone and bone
resorption7,37. Our data suggests that the initial requirements for actin ring formation are
transcriptional and are downstream of IKK, since RANK knockout cells can be induced
to form actin rings and resorb bone when expressing IKKβSSEE. In this setting, integrin
signaling at the bone-osteoclast interface most likely leads to actin organization. Our
discovery provides a direct approach to identify the essential components for
establishment of the actin ring.
NF-κB is a critical regulator of the inflammatory cellular program38, and
inflammatory cytokines have been linked to enhanced osteoclast function39,40. Since
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TNF-α has been shown to induce osteoclast differentiation in certain settings41, we sought
to determine whether this inflammatory factor was required for IKKβSSEE to induce
osteoclast differentiation. Using IKKβSSEE-transduced TNF-α knockout bone marrow
monocytes, we found that TNF-α is not required for IKKβSSEE to accomplish its effect in
osteoclast differentiation (Unpublished data, J.O. and Y.A.). Therefore, the mechanism
we observe for IKKβSSEE- induced osteoclastogenesis is uncoupled from inflammatory
signaling with respect to TNF. However, IKKβSSEE is capable of inducing secretion of
TNF by wild-type cells suggesting that this kinase may modulate osteoclastogenesis as
well as inflammatory osteolysis at varying levels.
Consistent with our in vitro findings, adenoviral gene transfer experiments
revealed that IKKβSSEE is also sufficient for the establishment of osteolysis in vivo. The
clinical significance of our findings is highlighted by our observations that IKKβSSEEinduced osteoclastogenesis is refractory to intervention with OPG and deletion of
RANK/RANKL. In this regard, a number of conditions in human patients are associated
with heightened bone turnover in the setting of inflammation for which a cause has not
been identified42. Given the potency with which activated IKKβ induces osteoclast
appearance and bone destruction in this model, it is important to consider IKKβ gain-offunction as an independent cause and a target in therapy for these and all conditions of
inflammatory bone destruction. Further, given the potency at which IKKβSSEE induces
bone resorption, this molecule positions itself as a strong therapeutic strategy for
osteopetrotic diseases.

82

In summary, our data highlight the critical role of IKKβ in osteoclast
differentiation and osteolysis. We have found that constitutively active IKKβ unfolds the
osteoclast program in the absence of upstream signals. This result raises the possibility
that other kinase effectors of RANK in osteoclast differentiation may be involved in
IKKβ activation. We report the first evidence of RANK-independent osteoclast
differentiation that is induced through a single kinase, and we propose that gain-offunction in human IKKβ may lead to a subset of genetic diseases resulting in bone
destruction which would be refractory to treatments targeting proximal RANK and TNF
signaling molecules.

METHODS:
Reagents. Antibodies against IKKβ, IKKα, IκBα, NEMO, Actin, RelA, RelB, c-Fos, cSrc, β3-Intergin, Histone H1, and horseradish peroxidase (HRP)-conjugated secondary
antibodies were from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Antibodies
against phospho- IKKβ, p100, and p105 were from Cell Signaling Technologies, Inc.
(Danvers, MA). Antibodies against Flag epitope were from Sigma (St. Louis, MO).
Antibody against V5 epitope was from Novus (Littleton, CO). Antibody against
Cathepsin K was from Millipore/Chemicon (Temecula, CA). HRP-conjugated secondary
antibody for immunohistochemistry was from Vector Laboratories (Burlingame, CA)
Cytokines were purchased from R&D Systems (Minneapolis, MN). All other chemicals
were purchased from Sigma (St. Louis, MO) unless otherwise indicated.
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Animals and Cells. All mice were housed in a controlled barrier facility at Washington
University (St. Louis, MO). TRAP Cre mice
Pittsburgh, PA). Floxed IKKβ

44

43

were from Dr. Roodman (University of

mice were from Dr. Pasparakis (University of Cologne,

Germany). TRAP Cre floxed/floxed IKKβ mice were generated by crossing TRAP Cre
transgenic mice with floxed IKKβ mice. IKKα heterozygous mice 19 were obtained from
Dr. Akira (Osaka University, Japan). RelB KO 45 and control bone marrow was from Dr.
Novack (Washington University, St. Louis, MO). RANK KO
well as NF-κB double KO

36

46

and control spleens as

and control spleens were provided by Dr. Xing (University

of Rochester Medical Center, N.Y.) For in vivo experiments, wild-type C57BL/6 mice at
5-6 weeks of age were used.

Plasmids. pMxs retroviral expression plasmid was from Dr. T. Kitamura (University of
Tokyo, Japan). Mouse cDNA for IKKα was kindly provided by Dr. Kenneth Marcu
(Stony Brook, NY). IKKβ and RelB cDNA were purchased from ATCC. RelA cDNA
was provided by Dr. C. Sasaki (NIA, Baltimore, MD). All expression constructs were
subcloned into pMxs using standard techniques. The following mutations were generated
using the QuickChange II Site Directed Mutagenesis Kit (Stratagene, La Jolla, CA) with
primer

pairs

in

parentheses:

IKKβSSEE

(IKKβ_S177_181E_f,

GAGCTGGATCAGGGCGAACTGTGCACGGAATTTGTGGGGACTCTGC,

and

IKKβ_S177_181E_r,
GCAGAGTCCCCACAAATTCCGTGCACAGTTCGCCCTGATCCAGCTC). Note that
the constitutive activating effect of this mutation of IKKβ has been established
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previously47,48.

IKKβSSAA

(IKKβ_S177_181A_f,

GAGCTGGATCAGGGCGCTCTGTGCACGGCATTTGTGGGGACTCTGC,

and

IKKβ_S177_181A_r,
GCAGAGTCCCCACAAATGCCGTGCACAGAGCGCCCTGATCCAGCTC);
IKKβWWAA

(IKKβ_W739_741A_f,

GACTCTAGACGCGAGCGCGTTACAGATGGAGGATG, and IKKβ_W739_741A_r,
CATCCTCCATCTGTAACGCGCTCGCGTCTAGAGTC); IKKβKM (IKKβ_K44M_f,
GTGAACAGATCGCCATCATGCAATGCCGACAGGAGC,

and

IKKβ_K44M_r,
IKKαSSEE

GCTCCTGTCGGCATTGCATGATGGCGATCTGTTCAC);
(IKKα_S176_180E_f,
GATGTTGATCAAGGAGAGCTCTGTACAGAATTTGTGGGAACATTGC,

and

IKKα-S176_180E_r,
GCAATGTTCCCACAAATTCTGTACAGAGCTCTCCTTGATCAACATC).

Generation

of

Bone

Marrow,

Spleen,

and

Fetal

Liver-Derived

Monocyte/Macrophages. Whole marrow was flushed from long bones into α- Minimum
Essential Medium (MEM). Spleens and d18.5 fetal livers were crushed into cell
suspensions in α-MEM and were centrifuged at 453 rcf. Cell pellets were resuspended in
whole media (α-MEM with 1X penicillin/streptomycin, 10% heat-inactivated fetal bovine
serum (FBS)). Monocytes/ macrophages were produced by growing cell suspensions in
the presence of 10 ng/ml M-CSF. Monocytes/ macrophages were allowed to proliferate
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for 3 days at 37 oC in 5% CO2 at which point they were infected with retrovirus. See
below.

Generation and Use of Retrovirus. The use of Plat-E retrovirus packaging cells stably
expressing retroviral structural proteins gag-pol and env for transient production of high
titer retrovirus was described previously49. Briefly, 8µg pMx vectors expressing our gene of
interest were transfected into 5 million plat-E cells (grown in DMEM supplemented with 10%
FBS, 10ng/ml M-CSF, and penicillin/streptomycin) using Fugene 6 (Roche, Palo Alto, CA)
according to manufacturer’s instructions. Twenty-four hrs post transfection, media was
exchanged to remove transfection reagent. Twenty-four and 48 hrs post media exchange,
supernatant was collected and pooled. In parallel, monocyte/macrophage cultures from bone
marrow, spleen, or fetal liver were developed on petri dishes, washed with PBS, and infected with
retrovirus in infection mix (50% virus supernatant, 50% αMEM containing 10% FBS, 10ng/ml
M-CSF, penicillin/streptomycin, and 4µg/ml hexadimethrine bromide). Twenty-four hrs post
infection,

cells

were

selected

in

αMEM

containing

10%

FBS,

10ng/ml

M-CSF,

penicillin/streptomycin, and 2µg/ml puromycin for 72 hrs, at which point selection media was
removed, cells were washed, and grown for 24 additional hrs without puromycin. At this point,
cells were lifted, counted, and plated for downstream experiments. Of note, IKKβSSEE-expressing
cells fused, spread, and assumed osteoclast morphology within 30 minutes of plating on a tissue
culture-treated surface, indicating that gene expression which occurred during viral transduction
and selection contributed to osteoclast differentiation. A representative image depicting this
phenomenon 30 min. post-plating is depicted in supplementary figure 2.
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In vitro Osteoclastogenesis. IKKβSSEE expressing cells were cultured in 10ng/ml MCSF, while GFP and IKKβWT-expressing cells were cultured in 10ng/ml M-CSF plus
100ng/ml RANKL for 4 days. IKKβSSEE induced spontaneous osteoclastogenesis in the
absence of RANKL, while RANKL was required for osteoclasts to form from
monocyte/macrophages expressing GFP or IKKβWT. At this point, cells were fixed and
TRAP stained using the Leukocyte Acid Phosphatase Kit (Sigma, St. Louis, MO). TRAPpositive cells with three or more nuclei were scored as osteoclasts.

Inhibitor Studies. For inhibition of osteoclastogenesis, cells were treated with 100ng/ml
OPG/Fc

Chimera

(R&D

Systems,

Minneapolis,

(YGRKKRRQRRR-G-TTLDWSWLQME)

or

MN),

25µM

25µM

TAT-NBD

TAT-mutant

NBD

(YGRKKRRQRRR-G-TTLDASALQME) during the entire course of retroviral
transduction and in vitro osteoclast differentiation. The efficacy of TAT-NBD in
inhibition of RANKL-induced osteoclastogenesis has been established previously 17.

RNA Isolation and cDNA Production. RNA was isolated from macrophage or
osteoclast cultures using the Total RNA Isolation Mini Kit (Agilent Technologies, Santa
Clara, CA) according to manufacturer’s instructions. Reverse transcription was
performed as follows: 1.0 μg RNA and 1.0 μg random hexamer primer in 10 μl nucleasefree deionized H2O in PCR tubes were heated to 70 oC for 5 minutes, cooled to 42 oC, and
set on ice. The following components were then added at the indicated amounts or
concentrations for a total reaction volume of 20 μl: 1x AMV RT buffer (Roche, Palo
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Alto, CA), 40U RNAseIn (Promega, San Luis Obispo, CA), 1.25 mM dNTPs, 5 mM
Sodium Pyruvate, 5 U Reverse Transcriptase Enzyme, AMV (Roche). To produce
cDNA, tubes were placed in a thermocycler programmed as follows: 42 oC for 60
minutes, 50 oC for 10 minutes, and 95 oC for 5 minutes.

Quantitative Real-Time PCR. Triplicate samples of 4 μl cDNA product (5X diluted),
10 μl Sybr Green PCR Master Mix (Applied Biosystems, Inc. Foster City, CA), 0.1 μl
each of 10 μM forward and reverse primer stocks, and 6 μL nuclease-free deionized H2O
were subjected to real-time PCR according to the following program in an ABI 7300 Real
Time PCR System: 50 oC for 2 minutes, 95 oC for 10 minutes, (95 oC for 15 seconds, 60
o

C for 1 minute) x 40 cycles. Results were analyzed using AB RQ Study Software. Real

Time PCR primers were designed using Primer Express Software (Applied Biosystems,
Inc.) mouse RANK Forward 5’-CTGCCTCCTGGGCTTCTTCT-3’, mouse RANK
Reverse

5’-CCCCTGGTGTGCTTCTAGCT-3’,

CGACCATTGTTAGCCACATACG-3’,

mouse

mouse

TRAP

TRAP

Forward
Reverse

5’5’-

CACATAGCCCACACCGTTCTC-3’,

mouse

Calcitonin

Receptor

Forward

5’-

CAAGAACCTTAGCTGCCAGAG-3’,

mouse

Calcitonin

Receptor

Reverse

5’-

CAAGCACGCGGACAATGTTG-3’,

mouse

Cathepsin

K

5’-

Reverse

5’-

GGAAGAAGACTCACCAGAAGC-3’,

mouse

Cathepsin

GTCATATAGCCGCCTCCACAG-3’,

mouse

β3

Integrin

Forward

5’-

TTACCCCGTGGACATCTACTA-3’,

mouse

β3

Integrin

Reverse

5’-

AGTCTTCCATCCAGGGCAATA-3’,

mouse
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GAPDH

K

Forward

Forward

5’-

CTTCACCACCATGGAGAAGGC-3’,

mouse

GAPDH

Reverse

5’-

GACGGACACATTGGGGGTAG-3’.

Western Blotting. Equivalent amounts of total cell protein were boiled in the presence of
an equal volume of 2X SDS sample buffer consisting of (0.5 M Tris-HCl, pH 6.8, 10%
(w/v) SDS, 10% glycerol, 0.05% (w/v) bromphenol blue, 3% β-Mercaptoethanol (v/v),
and distilled water) for 5 min. and subjected to electrophoresis on 8–10% SDS-PAGE.
Proteins were transferred to nitrocellulose membranes using a semi-dry blotter (Bio-Rad,
Hercules, CA) and incubated in blocking solution (10% skim milk prepared in phosphatebuffered saline containing 0.05% Tween 20) to reduce nonspecific binding. The
membranes were washed with PBS/Tween buffer and exposed to primary antibodies (16
h at 4 oC), washed (4 x 15 min.), and incubated with the appropriate secondary
horseradish peroxidase-conjugated antibodies (1 h at room temperature). The membranes
were washed extensively (4 X 15 min.), and an ECL detection assay was performed
following the manufacturer’s instructions.

Co-Immunoprecipitation. Cells expressing GFP, flag IKKβWT, flag IKKβWA, flag
IKKβSSEE, or flag IKKβSSEE/WA were lysed in immunoprecipitation (IP) buffer (10mM
Tris pH 7.4, 150mM NaCl, 0.5% NP-40 (IGEPAL) 1mM EDTA, 1mM NaF, 1mM
PMSF, 1mM Na3VO4, and 1X protease inhibitor cocktail) at 4oC. Protein was measured
by BCA Assay (Pierce, Rockford, IL) and normalized. Non-specific binding was
removed by rocking total cell lysate at 4oC with GammaBind G Sepharose beads (GE
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Lifesciences) and 100ng normal mouse IgG for 2 hrs at 4oC. Beads and normal antibody
were centrifuged and supernatant was incubated with GammaBind G Sepharose beads
and 1 µg/ml mouse anti-Flag M2 antibody (Sigma, St. Louis, MO) at 4oC for 16 hrs.
Immune complexes were centrifuged with beads. Supernatant was removed by vacuum
suction, and 2X sample buffer (0.5 M Tris-HCl, pH 6.8, 10% (w/v) SDS, 10% glycerol, 0.05%
(w/v) bromphenol blue, 3% β-Mercaptoethanol, and distilled water) was added to beads which

were boiled for 5 minutes to elute the complex components.

In vitro Kinase Assay. Plat E cells expressing indicated flag-tagged IKKβ constructs
were lysed in IP buffer. IKKβ was immunoprecipitated with M2 antibody, washed twice
with IP buffer, once with kinase assay buffer (Cell Signaling Technologies Danvers,
MA), and incubated for 30 minutes at 30oC in 30 µl kinase assay buffer with 1µg GSTIκBα, 2.5mM MgCl2, and 16µM ATP. Reaction was terminated with 30 µl reducing
sample buffer. Samples were analyzed by Western blot.

Bone Resorption Assays. Osteoclasts were cultured on 5mm2 100µm thick dentin slices
for 5 days in a 48-well tissue culture plate. To visualize resorption pits and tracks, slices
were exposed to 0.5N NaOH, and cells were removed by mechanical agitation. Slices
were washed in PBS three times and stained with 0.1% toluidine blue (w/v) in PBS for 10
minutes. Stained slices were rinsed with PBS and blotted dry, and pits were visualized by
light microscopy. For assessment of resorption of artificial bone matrix, macrophages or
osteoclasts were cultured on BD Biocoat Osteologic tissue culture slides (BD
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Biosciences, San Jose, CA) for 4 days, and resorption areas were determined as clear
areas in the osteologic matrix as visualized by light microscopy.

Actin Ring Staining. Macrophages expressing IKKβSSEE cultured on dentin in M-CSF
(IKKβSSEE-induced osteoclasts) or expressing GFP or IKKβWT cultured on dentin in MCSF or M-CSF + RANKL were fixed in 4% paraformaldehyde in PBS for 5 minutes at
room temperature. Fixed macrophages or osteoclasts on dentin slices were washed with
PBS three times and permeabilized in 0.2% Triton X 100 in PBS for 10 minutes at room
temperature. Dentin slices were washed three times with PBS and then incubated in a
1:40 dilution of Alexa Fluor-488 phalloidin (Invitrogen Molecular Probes, Eugene, OR)
for 10 minutes in a dark humidified chamber at room temperature. Slices were washed
with PBS and mounted onto microscope slides for visualization of actin rings with
fluorescent microscopy.

Generation and Use of Adenovirus. Adenovirus expressing IKKβSSEE was generated by
subcloning from the pMx parental vector into Ad5 CMV K-NpA Shuttle using EcoR1
and

Not1

restriction

endonucleases

(New

England

Biolabs,

Ipswich,

MA).

Recombination50, production and characterization (pfu/particle) of virus was provided by
Viraquest, Inc. (North Liberty, IA). For local in vivo gene transfer in mice, 1 x 107 pfu of
virus diluted in 10µl sterile PBS were injected intra-articularly into the knee joint
capsule. Contralateral knees on the same mouse served as experimental (Ad IKKβSSEE)
and control (AdntLacZ). For calvarial osteolysis, 1 x 107 pfu of virus diluted in 50µl
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sterile PBS were injected supracalvarially. Seven days post-injection, knees and calvariae
were fixed, decalcified, and analyzed histologically for osteoclasts and osteolysis. In
calvarial injection experiment, RANKL and LPS were used as positive controls for
osteolysis. 1µg mouse RANKL diluted in 50µl sterile PBS or 20µg LPS (055:B5 Sigma,
St. Louis, MO) diluted in 50µl sterile PBS were injected over calvaria. LPS and RANKL
were injected every-other-day.

X-Gal Staining. Bones were incubated at 37o C for 15 minutes in staining buffer
consisting of 2mM MgCl2, 5mM K3FE(CN)6, 5mM K4FE(CN)6, and 1mg/ml X-Gal in
PBS, pH 7.4.

Histology. Long bones and calvariae were collected from mice and fixed in 10% buffered
formalin for 24 hours. Bones were then decalcified for 7 days in decalcification buffer
consisting of (14% (w/v) EDTA, H4NOH pH 7.2), dehydrated in graded ethanol (30%70%), cleared through xylene, and embedded in paraffin. Paraffin sections were stained
histochemically for TRAP to visualize osteoclasts or H&E to assess tissue architecture.
Immunohistochemistry was performed according to antibody manufacturer’s instructions
for immunoperoxidase staining.

Microscopy. Cells and histological sections were imaged under white or ultraviolet light
on an inverted microscope (Olympus IX-51). For f-actin visualization, ultraviolet light
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was passed through a FITC filter cube to localize green phalloidin. Digital images were
captured using a CCD camera (Olympus DP70, 12 mega-pixel resolution).
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FIGURE LEGENDS
Figure 1. IKKβSSEE Induces bona fide Osteoclasts from Bone Marrow, Spleen, and
Fetal Liver Progenitors
(A) Bone marrow macrophages from IKKβ-KO and littermate mice were infected with
retroviruses expressing GFP, IKKβWT or IKKβSSEE and cultured with M-CSF alone or MCSF+RANKL for 4 days. Cells were fixed and TRAP stained to determine
osteoclastogenesis. Arrows denote osteoclasts. Lower panel, quantification; flx, loxP
flanked.
(B) Expression levels of IKKβWT and IKKβSSEE in control and IKKβ KO macrophages
were measured by Western blot. Expression of endogenous NEMO is shown as control.
(C) Western blot for expression of NF-κB molecules and osteoclast markers in total cell
lysates of spleen cells infected with indicated viruses. Actin expression indicates equal
loading. OC+, osteoclast positive control total cell lysate. (B and C) pMx, retroviral
expression vector.
(D) Relative expression of mRNA for osteoclast markers assessed by quantitative realtime PCR. GAPDH served as internal standard for cDNA normalization. Values are
expressed as relative quantity plus the standard error of the mean.
(E) Fetal liver cells (FLCs) were plated on dentin slices to determine bone resorbing
activity. Slices were stained with toluidine (Tol.) blue and phalloidin to visualize
resorption tracks (darker staining areas) and actin ring formation, respectively. Cells were
cultured in M-CSF alone except where indicated. Scale bars indicate magnification of
actin images.
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(F) Spleen macrophages infected with retrovirus expressing IKKβSSEE-EGFP Fusion
cultured in M-CSF were visualized by fluorescent microscopy (lower panel) and then
TRAP stained to visualize osteoclasts (upper panel). (G) Control and IKKβ KO
monocytes were transduced with viruses expressing GFP or the indicated forms of IKKβ.
These cells were treated with M-CSF and RANKL and TRAP stained to visualize
osteoclasts. (H) Western blot to demonstrate expression of the indicated IKKβ constructs.

Figure 2. IKKβSSEE-induced Osteoclastogenesis does not Require RANKL/RANK
Upstream Signals
(A) Bone marrow macrophages were cultured in the presence of M-CSF alone or in the
presence of M-CSF plus RANKL each in the absence or presence of OPG/Fc chimera.
IKKβSSEE- expressing cells were cultured with M-CSF in the absence or presence of
OPG/Fc chimera. Cells were TRAP stained to visualize osteoclasts.
(B) WT, RANK +/?, or RANK-/- spleen-derived macrophages were infected with a
retrovirus expressing GFP, IKKβWT, or IKKβSSEE. These cells were cultured in the
presence of M-CSF alone or in combination with RANKL for four days and TRAP
stained to visualize osteoclasts.
(C) WT and RANK-/- spleen-derived macrophages were infected with a retrovirus
expressing IKKβWT or IKKβSSEE. These cells were cultured in the presence of M-CSF
alone or in combination with RANKL for four days on dentin and were stained with
phalloidin or toluidine (Tol.) blue to visualize actin rings and resorption pits,
respectively. Scale bars indicate relative magnification of images.
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(D) WT (+/+) or RANK KO (-/-) spleen cells infected with the indicated viruses were
cultured in the presence of M-CSF or M-CSF + RANKL (RL), and total cell lysates were
analyzed by Wesern blot for expression of indicated proteins. Lower panel, quantitative
real-time PCR analysis to verify absence of RANK mRNA expression in RANK KO
cells. (E) Relative expression of mRNA for osteoclast markers assessed by quantitative
real-time PCR. GAPDH served as internal standard for cDNA normalization. Values are
expressed as relative quantity plus the standard error of the mean.

Figure 3. IKKβSSEE Induces Osteoclastogenesis Independent from NEMO
Association
(A) Bone marrow macrophages expressing IKKβSSEE were cultured in the presence of MCSF without NBD or with NBD or mutant NBD (mNBD). Cells expressing IKKβWT
were treated with RANKL to induce osteoclast differentiation in the absence of NBD or
in the presence of NBD or mNBD. Cells were TRAP stained for osteoclasts. Right panel,
quantification.
(B) Schematic diagram of IKKβ constructs utilized in (C and D). Kinase, kinase domain;
LZ, leucine zipper; HLH, helix-loop-helix; NBD, NEMO-binding domain. Not shown to
scale.
(C) Co-immunoprecipitation depicting ability of Tryptophan 739 and 741 to Alanine
mutations to prevent binding of IKKβWT and IKKβSSEE to NEMO.
(D) TRAP stain of cells expressing GFP or the IKKβ constructs shown in (B).
(E) Luciferase assay for NF-κB induction by constructs shown in (B).
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(F) Kinase assay for constructs shown in B. p-IκBα, phosphorylated IκBα.

Figure 4. IKKβSSEE Induction of Osteoclasts does not Require IKKα
(A) WT and IKKα-null FLCs expressing GFP were cultured with M-CSF in the absence
or presence of RANKL, or IKKβSSEE with M-CSF alone. TRAP staining for
osteoclastogenesis; phalloidin staining for actin ring formation; toluidine (Tol.) blue
staining for dentin resorption. Scale bars indicate magnification of actin image. (B)
Western blot for expression of selected NF-κB pathway markers. Actin blot shows equal
loading. OC+, osteoclast positive control. n.s., non-specific band. (C) Relative expression
of mRNA for selected markers of osteoclastogenesis assessed by quantitative real-time
PCR. Levels normalized to GAPDH.

Figure 5. IKKβSSEE Induction of Osteoclastogenesis Requires Coordinated NF-κB
Signaling
(A) Western blot for expression levels of key NF-κB signaling molecules in total cell
lysates (left panel) and cytosol and nuclear fractions (right panel) of spleen-derived
macrophages expressing GFP, IKKβWT, or IKKβSSEE not treated or treated with RANKL
for the indicated times.
(B) TRAP stain of WT and RelB KO bone marrow macrophages expressing IKKβSSEE
cultured in the presence of M-CSF without RANKL.
(C) Western blot for the indicated proteins in WT and RelB KO cells expressing GFP,
IKKβWT, or IKKβSSEE cultured with M-CSF. OC+, osteoclast positive control.
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(D) Relative mRNA expression of selected osteoclast markers in WT and Rel B KO cells
treated with RANKL or expressing IKKβSSEE not treated with RANKL.
(E and F) Protein expression and osteoclastogenesis, respectively, were measured
following expression of GFP, IKKβWT, IKKβSSEE, IKKαSSEE, p65(RelA), RelB, or
p65+RelB in bone marrow macrophages cultured with M-CSF.
(G-I) Control or NF-κB double knockout (dKO) spleen cells transduced with GFP,
IKKβWT, or IKKβSSEE were analyzed to determine (G) protein expression levels, (H)
osteoclastogenesis and bone resorption, and (I) Cathepsin K mRNA expression. Cells in
(I) were cultured in the presence of M-CSF without RANKL.

Figure 6. Active IKKβ is Sufficient for Osteolysis
(A) Images of TRAP stained histological slides of calvarial bones of mice injected
supracalvarially with adenovirus expressing lac Z (Ad LacZ) or IKKβSSEE (Ad
IKKβSSEE), LPS, or RANKL. Arrows indicate areas of osteoclastic bone erosion. Scale
bars, 200µm.
(B) Images of H&E, TRAP, and Immunoperoxidase-phospho-IκBα stained histological
slides of knees of mice injected intra-articularly with adenovirus expressing lac Z (Ad
LacZ) or IKKβSSEE (Ad IKKβSSEE). Arrows indicate areas of pathological osteoclastic
bone erosion at the articular surface (osteoclasts stain pink). Asterisks denote areas of
inflammatory cell infiltrate into the synovial space. Arrowheads show positive stain for
phosphorylated IκBα, indicative of active IKKβ. Objective used for capturing image is
labeled above panels. Scale bars, 200µm.
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Supplementary Figure 1. High Resolution Image Demonstrating RANKL-Independent
Osteoclastogenic Effect of IKKβSSEE in the Absence of Endogenous IKKβ. In an
independent experiment from figure 1A of main text, IKKβ KO cells were retrovirally
transduced with GFP, IKKβWT, or IKKβSSEE and were either cultured in M-CSF or MCSF + RANKL. Cells were TRAP stained to visualize osteoclasts (indicated with
arrows).

Supplementary Figure 2. IKKβSSEE-Transduced cells 30 min. Post-Plating. Image
capturing the phenomenon of the assumption of osteoclast morphology (arrows) by
IKKβSSEE but not GFP - expressing cells 30 minutes after plating on a tissue culture
surface. This observation indicates that gene expression which occurs during the
retroviral infection and selection process is responsible for osteoclast differentiation.

Supplementary Figure 3. Resorption of Artificial Matrix by Osteoclasts Generated by
Expression of IKKβSSEE. Spleen cells expressing IKKβWT and IKKβSSEE were grown in
M-CSF alone or in combination with RANKL and were TRAP stained or plated on
osteologic (Osteo.) substrate to assess osteoclast activity. Clear areas indicated by
arrowheads represent osteoclastic resorption of substrate.
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Supplementary Figure 4. High Resolution Image of Resorption Pits Generated by
RANKL and IKKβSSEE – Induced Osteoclasts. Monocytes were retrovirally transduced
with either IKKβWT or IKKβSSEE. Cells were then plated on dentin slices and grown in the
presence of M-CSF (IKKβSSEE) or M-CSF + RANKL (IKKβWT) for 5 days. Slices were
stained with toluidine blue and visualized by light microscopy. This high resolution
image depicts the regular pattern of the dentin slice best visualized when not resorbed
(IKKβWT in M-CSF). Arrows indicate resorption pits and tracks which appear as dark
staining irregularities in the dentin slice.

Supplementary Figure 5. Constitutive IκBα Processing Induced by IKKβSSEE in Control
and NF-κB dKO Cells. Monocytes were retrovirally transduced with either GFP,
IKKβWT, or IKKβSSEE. Total cell lysates were immunoblotted for the indicated proteins.
This data indicates that basal IκBα level is normal in the absence of subunits NF-κB1 and
2. IKKβSSEE induces constitutive processing of IκBα independently from these two
subunits, but this phenomenon is insufficient to induce osteoclasts without NF-κB1 and
2. OC+, osteoclast positive control.

Supplementary Figure 6. Adenoviral Gene Transfer in vivo. Knees of mice were intraarticularly injected with adenovirus expressing LacZ or IKKβSSEE. One week postinjection, legs were analyzed by X-gal staining for LacZ expression. Retro-patellar
location of blue stain (arrowhead) indicates the intra-joint localization of gene expression.
Scale bar, 1 cm.
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Supplementary Figure 7. Kinase Activity is responsible for IKKβSSEE-induced
osteoclastogenesis. (A) Spleen macrophages were infected with retrovirus expressing
GFP, IKKβ, IKKβSSEE, or IKKβSSEE

KM

. Cells were TRAP-stained to visualize

osteoclasts. (B) NF-κB luciferase and (C) in vitro kinase assays for indicated constructs.
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CHAPTER 4
INFLAMMATORY CYTOKINE SECRETION AND
OSETOCLAST DIFFERENTIATION INDUCED BY ACTIVATION
OF IKKβ IN MACROPHAGES ARE UNCOUPLED EVENTS

122

ABSTRACT

We have previously demonstrated that constitutively active IKKβ (IKKβSSEE) induces a
program for differentiation of fully functional osteoclasts in the absence of RANK
signaling. This finding, coupled with the fact that IKKβ is required for normal osteoclast
differentiation in response to RANKL treatment of macrophages, argues that IKKβ
activation is necessary for osteoclast differentiation and constitutive activation of IKKβ is
sufficient. It is known that IKKβ activates NF-κB which is an inducer of both
osteoclastogenic and inflammatory signals. We sought to determine whether
inflammatory signals contribute to the osteoclastogenic effect of constitutively active
IKKβ in macrophages. We confirmed that, in conjunction with induction of
osteoclastogenesis, IKKβSSEE induces expression of both TNFα and IL-1β, two proinflammatory cytokines linked to osteoclastogenesis and inflammatory osteolysis.
However, using macrophages genetically deficient in TNFα or the IL-1 type 1 receptor,
we determined that neither TNFα nor IL-1β are required for osteoclast differentiation
induced by IKKβSSEE. These results confirm that in vitro, osteoclast differentiation and
the cellular inflammatory response, with respect to TNFα and IL-1 are uncoupled.
Furthermore, we confirm that pure activation IKKβ is capable of inducing
osteoclastogenesis from macrophages in an autocrine stimulation-independent, cellautonomous manner.
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INTRODUCTION

Rheumatoid Arthritis (RA) is an autoimmune disease characterized by chronic
inflammation of the joints resulting in joint pain, swelling, immobility, and deformity.
Although the initiating event responsible for RA is unknown, several factors are believed
to play a role in the pathogenesis of the disease. It is known that several cell types interact
in the inflamed joint and contribute to the progression of RA including synovial
fibroblasts and lymphocytes, which secrete pro-inflammatory factors, and osteoclasts
which degrade bone in response to these factors 1. The role of cytokines in progression of
RA is well established 2. For example, synovial mononuclear cell cultures from patients
affected by RA were demonstrated to produce the pro-inflammatory cytokine, TNFα 3,
which was later localized to the inflamed synovial membrane in tissue sections of RA
patients4. Further, mice engineered to express high levels of human TNFα develop
spontaneous arthritis with cartilage and bone destruction 5, and neutralizing antibodies
against TNFα significantly reduced the clinical severity of arthritis in a murine model for
the disease 6. It is believed that TNFα contributes to the bone destruction mediated by
osteoclasts in arthritis 7. Whether TNF itself is sufficient for osteoclast differentiation

8,9

or whether TNF enhances established osteoclastogenesis 10 is controversial, but it is clear
that osteoclasts are necessary for TNF-mediated bone destruction

11

. IL-1 is another

cytokine known to contribute to the pathogenesis of arthritis as IL-1 gene expression has
been demonstrated in the synovium of patients with RA 12, and IL-1 blockade ameliorates
the joint destruction associated with experimental arthritis in mice 13. The role of IL-1 in
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mediating bone destruction in arthritis has been suggested based on the observation that
IL-1 knockout mice were resistant to TNF-mediated bone destruction

14

and that IL-1 is

essential for TNF-mediated osteoclastogenesis in vitro 15. Factors that influence TNF and
IL-1 expression in the setting of RA are candidate targets in the treatment of the bone
destruction associated with the disease.

NF-κB is a family of transcription factors that plays a critical role in the inflammatory
response 16. It is known that TNF and IL-1 are gene targets for NF-κB 17,18 and that these
cytokines also activate NF-κB

19,20

creating a positive feedback loop which may

contribute to chronic inflammatory diseases. It has been shown in mice that disruption of
NF-κB or upstream activators of NF-κB are resistant to different models for
inflammatory arthritis and bone destruction 21-25. Given the therapeutic value of TNF and
IL-1 blockade in arthritis 2, it is likely that NF-κB mediated activation of TNF and IL-1
contributes to the inflammation and bone destruction associated with arthritis. We
wondered whether osteoclastogenesis driven by constitutive activation of NF-κB
(reported in Chapter 3 of this thesis) was a result of continuous secretion and therefore
autocrine stimulation of monocytes by TNF or IL-1.

We used retrovirus mediated delivery of constitutively activated IKKβ (IKKβSSEE) into
monocytes to activate NF-κB, and we demonstrated that in response to IKKβSSEE, TNFα
and IL-1β are upregulated at both mRNA and protein levels. However, TNFα and IL-1R
knockout monocytes were stimulated to become osteoclasts in response to IKKβSSEE,
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which demonstrates that pro-inflammatory autocrine signaling does not contribute to
spontaneous osteoclast differentiation driven by constitutively active IKKβ. These
observations suggest that IKKβ-driven transcriptional activity within IKKβSSEE –
expressing monocytes leads to osteoclast differentiation in a cell-autonomous manner,
which provides strong evidence that osteoclast differentiation can be stimulated by a
single signaling pathway downstream of RANK.

RESULTS

Constitutively Active IKKβ Induces both Pro-Inflammatory and Osteoclastogenic
Programs

NF-κB is an important stimulator of the production of the inflammatory cytokines, TNF
and IL-1

17,18

. We have shown that constitutively active IKKβ (IKKβSSEE), which is an

upstream activator of NF-κB, triggers osteoclast differentiation from monocytes in the
absence of RANKL. Since TNF and IL-1 have been demonstrated to induce
osteoclastogenesis in certain settings independent from the RANKL/RANK signaling
pathway 9, we sought to determine whether IKKβSSEE induces production of TNF and IL1 in macrophages and, further, whether these molecules are responsible for triggering
spontaneous osteoclast differentiation promoted by IKKβSSEE. We confirmed by Western
blot that IKKβSSEE but not WT IKKβ induced nuclear translocation of p65/RelA in
macrophages, which demonstrates the ability of phosphomimmetic Serine to Glutamic
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Acid mutations in the t-loop of IKKβ to activate NF-κB in macrophages (Fig. 1). In a
culture system in which wild-type bone marrow macrophages were induced by IKKβSSEE
to differentiate into mature osteoclasts (Fig. 2A), we measured production of the mRNA
for the osteoclastogenic cytokine, RANKL, and its receptor RANK. We determined that
RANKL mRNA was not detectible in our culture system in GFP, WT IKKβ, or IKKβSSEE
expressing cells (Fig. 2B), suggesting that IKKβSSEE induces osteoclastogenesis without
positive feedback by RANKL. Furthermore, mRNA for the receptor RANK was not
induced by IKKβSSEE (Fig. 2B), which argued against the possibility that IKKβSSEE –
expressing cells may be more sensitive to undetectable levels of RANKL in the culture
through receptor upregulation. This result is consistent with our previous findings in
which we show that the osteoclastogenic effect of IKKSSEE is a RANK/RANKLindependent event. Next, to determine whether activation of IKKβ in macrophages results
in production of pro-inflammatory cytokines, we measured mRNA levels for the proinflammatory cytokines, TNFα and IL-1β. We determined that IKKβSSEE induces
increased expression of mRNA for both TNFα and IL-1β compared with GFP and WT
IKKβ – expressing macrophages (Fig. 2C). Interestingly, TNFα mRNA level was only
induced 3 fold, while mRNA for IL-1β was increased by more than 1000 fold (Fig. 2C).
Nevertheless, the level of TNFα protein secreted into the culture media measured by
ELISA was 7.8 fold greater in IKKβSSEE – expressing cells compared with GFP
expressing cells (p<0.005), and IL-1β protein measured in the media of IKKβSSEE –
expressing cells was 22.6 fold greater than in the media of GFP – expressing cells
(p<0.005) (Fig. 2D). WT IKKβ did not induce increased TNFα or IL-1β protein secretion
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from macrophages compared with GFP. These results demonstrate that in macrophages,
constitutively active IKKβ induces secretion of pro-inflammatory cytokines, which have
been shown to contribute to osteoclast differentiation 8-10,15.

TNFα is Dispensable for Induction of Spontaneous Osteoclast Formation by IKKβSSEE

Whether TNFα or IL-1β was a causative factor for osteoclastogenesis in response to
activation of IKKβ was unclear. To address this question, we tested the ability of
IKKβSSEE to induce osteoclastogenesis from bone marrow macrophages isolated from
TNFα knockout mice, which are defective in TNFα production

26

. We retrovirally

expressed either GFP, WT IKKβ, or IKKβSSEE in WT and TNFα KO macrophages.
Western blot revealed equivalent expression of IKKβ constructs (Fig. 3A). However,
although IKKβSSEE induced secretion of TNFα from WT macrophages, this induction did
not occur in TNFα KO macrophages (Fig. 3B). Nevertheless, TNFα KO macrophages
were induced by IKKβSSEE to become osteoclasts to the same extent as WT macrophages
(Fig. 3C), indicating that IKKβSSEE – induced TNFα autocrine stimulation of
macrophages is not responsible for the spontaneous osteoclast differentiation induced by
constitutive activation of IKKβ. Interestingly, we observed reduced IL-1β secretion by
TNFα KO compared with WT macrophages expressing IKKβSSEE (p<0.005) (Fig. 3D).
Therefore, active IKKβ partially relies on TNFα for maximal IL-1β production, but
reduced IL-1β production in the TNFα – null setting does not result in impaired
spontaneous osteoclast differentiation.
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IL-1 Does Not Mediate the Osteoclastogenic Effect of Constitutively Active IKKβ

To determine whether constitutively active IKKβ requires IL-1β autocrine stimulation to
induce osteoclastogenesis, we tested the ability of IKKβSSEE to induce osteoclasts from
macrophages lacking the IL-1α/β type 1 receptor

27

. IL-1 signaling is required for

osteoclast bone erosion in response to systemic inflammation 14, so the possibility exists
that IKKβSSEE may induce osteoclast differentiation through production of IL-1. We
observed that although IL-1β failed to enhance RANKL-mediated osteoclastogenesis
from IL-1 receptor knockout macrophages (Fig 4 A. B), these cells were not defective in
osteoclastogenesis induced by expression of IKKβSSEE(Fig 4 B), despite equivalent
expression of IKKβ constructs in WT and IL-1 receptor knockout macrophages (Fig 4
C). These results indicate that IL-1 does not mediate the osteoclastogenic effect of
constitutive activation of IKKβ.

DISCUSSION

Osteoclastogenesis in the setting of inflammation has been widely documented

28-30

, and

it is known that NF-κB is a critical mediator of both inflammatory as well as
osteoclastogenic signaling

31

. We discovered that constitutively activating NF-κB by

expressing active IKKβ (IKKβSSEE) in monocytes induces osteoclast differentiation
without upregulating RANKL or its receptor, RANK. We therefore hypothesized that
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constitutively active IKKβ induced osteoclast differentiation either from within the
monocyte in a cell-autonomous fashion or through secretion of and autocrine stimulation
by pro-inflammatory mediators. Although RANKL, the most important osteoclastogenic
cytokine, is required for inflammatory osteoclastogenesis in response to certain in vivo
models of arthritis 32, it has been proposed that the inflammatory cytokines TNF and IL-1
may compensate for RANKL to induce osteoclast differentiation from isolated
monocytes 8,9. Since activation of NF-κB is associated with production of TNF and IL-1
17,18

, we sought to determine whether IKKβSSEE induced osteoclast differentiation through

these pro-inflammatory cytokines. In addition to stimulation of osteoclast differentiation,
we observed induction of both TNFα and IL-1β secretion by macrophages expressing
constitutively active IKKβ. However, genetic disruption of TNF or the IL-1 type 1
receptor had no effect on the osteoclastogenic phenotype induced by IKKβSSEE.
Therefore, we have demonstrated that there are separate and exclusive programs for
osteoclast differentiation and inflammation induced downstream of IKKβ activation.
Furthermore, the fact that autocrine stimulation by TNFα and IL-1β does not mediate
osteoclast differentiation induced by constitutively active IKKβ strongly suggests that the
program for osteoclastogenesis can be encoded entirely through NF-κB downstream of
IKKβ. This finding, in addition to the fact that IKKβ is required for osteoclast
differentiation induced by RANKL 33, supports the notion that IKKβ is a critical target in
treating inflammatory bone erosion and other osteoclast – mediated diseases.
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METHODS

Reagents: Antibodies against IKKβ, Actin, and RelA as well as horseradish peroxidaseconjugated secondary antibodies were purchased from Santa Cruz Biotechnology, Inc.
(Santa Cruz, CA). Antibody against Flag epitope was purchased from Sigma (St. Louis,
MO). Cytokines were purchased from R&D Systems (Minneapolis, MN). Enhanced
Chemiluminescence kit was purchased from Pierce Biotechnology, Inc (Rockford, IL).
All other chemicals were purchased from Sigma (St. Louis, MO) unless otherwise
indicated.

Animals: All mice were purchased from Jackson Laboratories (Bar Harbor, Maine) and
were housed in a controlled barrier facility at Washington University (St. Louis, MO).

Plasmids: pMxs retroviral expression plasmid was a generous gift from Dr. Toshio
Kitamura (University of Tokyo, Japan). IKKβ cDNA was purchased from ATCC,
I.M.A.G.E. Clone ID #4482634. All expression constructs were subcloned into pMxs
using standard techniques. The following mutations were generated using the
QuickChange II Site Directed Mutagenesis Kit (Stratagene, La Jolla, CA) with primer
pairs

in

IKKβSSEE

parentheses:

(IKKβ_S177_181E_f,

GAGCTGGATCAGGGCGAACTGTGCACGGAATTTGTGGGGACTCTGC,

and

IKKβ_S177_181E_r,
GCAGAGTCCCCACAAATTCCGTGCACAGTTCGCCCTGATCCAGCTC). Note that
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the constitutive activating effect of this mutation of IKKβ has been established previously
34,35

.

Macrophage Culture: Whole marrow was flushed from long bones into α- Minimum
Essential Medium (MEM). Spleens were crushed into cell suspensions in α-MEM and
were centrifuged at 453 rcf. Cell pellets were resuspended in whole media (α-MEM with
1X penicillin/streptomycin, 10% heat-inactivated fetal bovine serum (FBS)). Monocytes/
macrophages were produced by growing cell suspensions in the presence of 10 ng/ml MCSF. Monocytes/ macrophages were allowed to proliferate for 3 days at 37 oC in 5% CO2
at which point they were infected with retrovirus. See below.

Infection of Macrophages: The use of Plat-E retrovirus packaging cells stably expressing
retroviral structural proteins gag-pol and env for transient production of high titer
retrovirus was described previously

36

. Briefly, 8µg pMx vectors expressing our gene of

interest were transfected into 5 million plat-E cells (grown in DMEM supplemented with 10%
FBS, 10ng/ml M-CSF, and penicillin/streptomycin) using Fugene 6 (Roche, Palo Alto, CA)
according to manufacturer’s instructions. Twenty-four hrs post transfection, media was
exchanged to remove transfection reagent. Twenty-four and 48 hrs post media exchange,
supernatant was collected and pooled. In parallel, monocyte/macrophage cultures from bone
marrow, spleen, or fetal liver were developed on petri dishes, washed with PBS, and infected with
retrovirus in infection mix (50% virus supernatant, 50% αMEM containing 10% FBS, 10ng/ml
M-CSF, penicillin/streptomycin, and 4µg/ml hexadimethrine bromide). Twenty-four hrs post
infection,

cells

were

selected

in

αMEM
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containing

10%

FBS,

10ng/ml

M-CSF,

penicillin/streptomycin, and 2µg/ml puromycin for 72 hrs, at which point selection media was
removed, cells were washed, and grown for 24 additional hrs without puromycin. At this point,
cells were lifted, counted, and plated for downstream experiments.

Osteoclast Differentiation: IKKβSSEE expressing cells were cultured in 10ng/ml M-CSF,
while GFP and IKKβWT-expressing cells were cultured in 10ng/ml M-CSF plus 100ng/ml
RANKL for 4 days. IKKβSSEE induced spontaneous osteoclastogenesis in the absence of
RANKL,

while

RANKL

was

required

for

osteoclasts

to

form

from

monocyte/macrophages expressing GFP or IKKβWT. At this point, cells were fixed and
TRAP stained using the Leukocyte Acid Phosphatase Kit (Sigma, St. Louis, MO). TRAPpositive cells with three or more nuclei were scored as osteoclasts.

Western Blot: Equivalent amounts of total cell protein were boiled in the presence of an
equal volume of 2X SDS sample buffer consisting of (0.5 M Tris-HCl, pH 6.8, 10%
(w/v) SDS, 10% glycerol, 0.05% (w/v) bromphenol blue, 3% β-Mercaptoethanol (v/v),
and distilled water) for 5 min. and subjected to electrophoresis on 8–10% SDS-PAGE.
Proteins were transferred to nitrocellulose membranes using a semi-dry blotter (Bio-Rad,
Hercules, CA) and incubated in blocking solution (10% skim milk prepared in phosphatebuffered saline containing 0.05% Tween 20) to reduce nonspecific binding. The
membranes were washed with PBS/Tween buffer and exposed to primary antibodies (16
h at 4 oC), washed (4 x 15 min.), and incubated with the appropriate secondary
horseradish peroxidase-conjugated antibodies (1 h at room temperature). The membranes
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were washed extensively (4 X 15 min.), and an ECL detection assay was performed
following the manufacturer’s instructions.

Enzyme Linked Immunosorbent Assay: Supernatants were collected from 6-well plates
of 1x106 cells expressing various constructs and were rapidly frozen at -80oC. TNFα or
IL-1β concentrations were measured in thawed supernatants by ELISA using Quantikine
kits from R&D Systems (Minneapolis, MN).

Isolation of RNA and cDNA Production: RNA was isolated from macrophage or
osteoclast cultures using the Total RNA Isolation Mini Kit (Agilent Technologies, Santa
Clara, CA) according to manufacturer’s instructions. Reverse transcription was
performed as follows: 1.0 μg RNA and 1.0 μg random hexamer primer in 10 μl nucleasefree deionized H2O in PCR tubes were heated to 70 oC for 5 minutes, cooled to 42 oC, and
set on ice. The following components were then added at the indicated amounts or
concentrations for a total reaction volume of 20 μl: 1x AMV RT buffer (Roche, Palo
Alto, CA), 40U RNAseIn (Promega, San Luis Obispo, CA), 1.25 mM dNTPs, 5 mM
Sodium Pyruvate, 5 U Reverse Transcriptase Enzyme, AMV (Roche). To produce
cDNA, tubes were placed in a thermocycler programmed as follows: 42 oC for 60
minutes, 50 oC for 10 minutes, and 95 oC for 5 minutes.
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Quantitative Real-Time PCR: Triplicate samples of 4 μl cDNA product (5X diluted), 10
μl Sybr Green PCR Master Mix (Applied Biosystems, Inc. Foster City, CA), 0.1 μl each
of 10 μM forward and reverse primer stocks, and 6 μL nuclease-free deionized H2O were
subjected to real-time PCR according to the following program in an ABI 7300 Real
Time PCR System: 50 oC for 2 minutes, 95 oC for 10 minutes, (95 oC for 15 seconds, 60
o

C for 1 minute) x 40 cycles. Results were analyzed using AB RQ Study Software. Real

Time PCR primers were designed using Primer Express Software (Applied Biosystems,
Inc.) mouse RANK Forward 5’-CTGCCTCCTGGGCTTCTTCT-3’, mouse RANK
Reverse

5’-CCCCTGGTGTGCTTCTAGCT-3’;

CCTGAGGCCCAGCCATTT-3’

mouse

mouse

AGCCTCGATCGTGGTACCAA-3’;

RANKL

Forward

5’-

RANKL

Reverse

5’-

TNFα

Forward

5’-

mouse

GACACCATGAGCACAGAAAGCATGATCCGC-3’

mouse

TNFα

Reverse

5’-

CGAAGTTCAGTAGACAGAAGAGCGTGGTGG-3’;

mouse

IL-1β

Forward

5’-

GCTTCCTTGTGCAAGTGTCTGA-3’

mouse

IL-1β

Reverse

5’-

TCAAAAGGTGGCATTTCACAGT-3’.

Microscopy: Cells were imaged under white light on an inverted microscope (Olympus
IX-51). Digital images were captured using a CCD camera (Olympus DP70, 12 megapixel resolution).

Statistics: Students two-tailed T-test for comparison between means was used for all
analyses.
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FIGURE LEGENDS

Figure 1: Constitutively Active IKKβ Induces NF-κB Nuclear Translocation
WT macrophages were infected (infx) with retroviruses expressing GFP or flag-tagged
WT IKKβ or IKKβSSEE for either 0, 1, 2, 4, or 6 days. Nuclei were extracted and blotted
for p65/RelA (lower two panels). Cytosolic fraction was blotted with flag antibody to
detect retrovirally expressed IKKβ (upper pannel). ns, non-specific antibody reactivity;
N, nucleus; C, cytosol.

Figure 2: Induction of Osteoclastogenesis and Inflammatory Cytokine Secretion by
IKKβSSEE
WT macrophages were infected with retroviruses expressing GFP, WT IKKβ (WT), or
IKKβSSEE (SSEE). (A) Cells were plated for osteoclastogenesis. GFP, WT IKKβ, and
IKKβSSEE expressing cells were cultured in M-CSF alone. Where indicated, WT IKKβ –
expressing cells were treated with RANKL to induce osteoclastogenesis. Cells were
TRAP-stained to visualize osteoclasts. (B) mRNA was collected from cells, and RANK
and RANKL gene expression were measured by quantitative real-time PCR. MC3T3,
mouse bone stromal cell line. Values are expressed as mean quantitation plus standard
error of the mean. (C) TNFα and IL-1β gene expression levels were measured by
quantitative real-time PCR. Values are expressed as mean quantitation plus standard error
of the mean. (D) Media supernatants were harvested from cultures of macrophages (or
osteoclasts in the case with IKKβSSEE-expressing cells) expressing the indicated
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constructs. TNFα and IL-1β protein concentrations were measured by ELISA. (*),
p<0.005.

Figure 3: TNFα Autocrine Stimulation is not Responsible for IKKβSSEE – Induced
Osteoclastogenesis. (A) Macrophages from TNF KO and WT littermates were collected
and infected with retroviruses expressing either GFP, WT IKKβ, or IKKβSSEE. Cells were
lysed and total IKKβ protein was detected by Western blot. Actin was blotted as a
loading control. (B) Media supernatant was collected from cultures of cells expressing
either GFP, WT IKKβ, or IKKβSSEE. TNFα protein concentration in media was measured
by ELISA. (**), p<0.001. (C) Cells were grown in media supplemented with M-CSF
(without RANKL) and were TRAP-stained to visualize osteoclasts. (D) Media
supernatant was collected from cultures of WT and TNFα KO cells expressing either
GFP, WT IKKβ, or IKKβSSEE. IL-1β protein concentration in media was measured by
ELISA. (*), p<0.005

Figure 4: IL-1 Receptor Autocrine Stimulation is not an Essential Mediator of the
Osteoclastogenic Effect of Constitutively Active IKKβ. (A) Macrophages were isolated
from WT or IL-1 receptor knockout mice and were infected with retroviruses expressing
either GFP, WT IKKβ (WT), or IKKβSSEE (SSEE). Cells were grown in the presence MCSF (without RANKL) or were supplemented with RANKL or RANKL and IL-1β as
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indicated. Cells were TRAP-stained to visualize osteoclasts. (B) Quantification of (A).
(C) Expression of IKKβ constructs in cells from (A).
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CHAPTER 5
ACTIVATION OF THE ALTERNATIVE NF-κB PATHWAY
BY CONSTITUTIVELY ACTIVE IKKβ
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INTRODUCTION

NF-κB is a family of transcription factors which serves diverse functions in development,
immunity, and bone metabolism. Traditionally, NF-κB signaling is divided into two
pathways, classical (canonical) and alternative (non-canonical)

1,2

. In classical NF-κB

signaling, extracellular signals such as TNF or IL-1, activate an IKK complex comprising
IKKα, IKKβ, and IKKγ (NEMO). IKK then phosphorylates IκBα, which holds NF-κB in
the cytoplasm in an inactive state. Upon phosphorylation, IκBα becomes ubiquitinated
and rapidly degraded by the proteasome. Classical NF-κB heterodimers consisting of p50
and p65/RelA are released from cytoplasmic sequestration, enter the nucleus, and activate
gene transcription. In the alternative signaling pathway, signals from cytokines such as
BAFF and lymphotoxin β lead to activation of IKKα which phosphorylates the Cterminal IκB portion of NF-κB p100. This event results in ubiquitination and proteosomal
processing of p100 to p52 leading to nuclear translocation of the p52/RelB heterodimer
and gene transcription 3.

The ability of the two NF-κB pathways to interact or be coordinated at multiple levels has
been suggested. For example, RANKL, the pro-osteoclastogenic cytokine, is known to
activate both classical and alternative NF-κB
shown to activate both IKKβ

6

and IKKα

7,8

4,5

. In addition, the kinase, NIK, has been

, responsible for activation of classical and

alternative NF-κB signaling, respectively. Furthermore, the level and activity of RelB, the
alternative NF-κB signaling pathway transactivator, are set by activity of the classical
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pathway 9. The inability of these two pathways to compensate for each other in
development highlights the notion that they are indeed separate signaling modules 10, but
whether they are coordinated in disease states is unknown. Interestingly, constitutive
activation of classical NF-κB has been demonstrated to compensate for absence of
alternative signaling through BAFFR in B-cell development 11, raising the possibility that
activation of IKKβ may regulate alternative signaling in certain settings.

We have shown that constitutively active IKKβ is capable of inducing osteoclastogenesis
from monocytes in the absence of IKKα, a setting in which alternative NF-κB signaling
induced by RANKL is inhibited. We now demonstrate that constitutively active IKKβ
(IKKβSSEE) induces nuclear translocation of RelB in monocytes. This event is likely a
result of processing of p100 to p52, which we show can be induced by IKKβSSEE in the
absence of IKKα. Whether the activation of RelB by IKKβSSEE contributes to the
osteoclast differentiation observed in the absence of IKKα is unclear. Further, it is
uncertain whether alternative NF-κB can be activated by IKKβ in pathological settings. It
will be important to identify the mechanism by which constitutive activation of IKKβ
leads to RelB nuclear translocation, as this will lead to a better understanding of NF-κB
regulation in the setting of normal physiology and disease.
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RESULTS

Constitutively Active IKKβ Induces RelB Nuclear Translocation

A signature of RANKL-induced osteoclast differentiation is activation of both Classical
and Alternative NF-κB signaling 4,5,12. We have shown that constitutive activation of NFκB by IKKβSSEE results in differentiation of osteoclasts. Although this phenomenon was
also observed in the absence of RelB, we noted that RelB protein levels were
constitutively increased in cells expressing IKKβSSEE, but not WT IKKβ. We sought to
determine whether in addition to increased RelB expression, IKKβSSEE also induced RelB
nuclear translocation. We performed nuclear/cytosolic fractionation in monocytes, which
we infected with retroviruses expressing GFP, WT IKKβ, or IKKβSSEE. We observed that
indeed, RelB was induced to enter the nucleus after 4 days of infection with IKKβSSEE,
but not WT IKKβ or GFP (Fig. 1). This indicates that constitutive activation of IKKβ,
normally considered an activator of the Classical NF-κB pathway, can also activate the
Alternative NF-κB pathway in monocytes.

Constitutively Active IKKβ Induces p100 Processing to p52

We sought to determine the mechanism responsible for IKKβSSEE – induced RelB nuclear
translocation. It is known that p100 processing to p52 is required for activation of the
Alternative NF-κB pathway

2,8

. We hypothesized that IKKβSSEE may induce processing
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of p100 to p52 resulting in RelB activation. We expressed GFP, WT IKKβ, and IKKβSSEE
in WT and NF-κB1/2 double knockout (DKO) monocytes. We observed that IKKβSSEE,
but not WT IKKβ or GFP, induced production of p52 in WT but not NF-κB1/2 DKO
monocytes (Fig. 2). The absence of p52 in cells lacking the precursor, p100, suggests the
authenticity of the p52 product. The ability of WT IKKβ and IKKβSSEE to induce
processing of IκBα even in the absence of NF-κB1 and NF-κB2 demonstrates that NF-κB
is not required for IKKβ activity.

Production of p52 by IKKβSSEE does not require IKKα

It is known that NIK activates the alternative NF-κB pathway through IKKα

13

. We

wondered whether IKKα is required for IKKβSSEE mediated p52 processing. We
expressed GFP or IKKβSSEE in WT and IKKα KO fetal liver – derived monocytes and
detected p52 expression by Western blot. We observed that even in the absence of IKKα,
IKKβSSEE induced the processing of p100 to p52 (Fig. 3). This result suggests that active
IKKβ may act on p100 directly to produce p52 and activate the alternative NF-κB
pathway. It will be important to determine whether this crosstalk between classical and
alternative NF-κB signaling has functional significance in the setting of bone pathology.
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METHODS

Reagents: Antibodies against IKKβ, Actin, IκBα, and RelB as well as horseradish
peroxidase-conjugated secondary antibodies were purchased from Santa Cruz
Biotechnology, Inc. (Santa Cruz, CA). Antibody against Flag epitope was purchased
from Sigma (St. Louis, MO). Antibodies against IKKα and p100/p52 were from Cell
Signaling Technologies, Inc (Danvers, MA). Cytokines were purchased from R&D
Systems (Minneapolis, MN). Enhanced Chemiluminescence kit was purchased from
Pierce Biotechnology, Inc (Rockford, IL). All other chemicals were purchased from
Sigma (St. Louis, MO) unless otherwise indicated.

Animals and Cells: All mice were housed in a controlled barrier facility at Washington
University (St. Louis, MO). IKKα heterozygous mice
(Osaka University, Japan). RelB KO

5

12

were obtained from Dr. Akira

and control bone marrow was obtained from Dr.

Novack (Washington University, St. Louis, MO). NF-κB double KO

14

and control

spleens were a generous gift from Dr. Lianping Xing (University of Rochester Medical
Center, N.Y.)

Plasmids: pMxs retroviral expression plasmid was a generous gift from Dr. Toshio
Kitamura (University of Tokyo, Japan). IKKβ cDNA was purchased from ATCC,
I.M.A.G.E. Clone ID #4482634. All expression constructs were subcloned into pMxs
using standard techniques. The following mutations were generated using the
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QuickChange II Site Directed Mutagenesis Kit (Stratagene, La Jolla, CA) with primer
pairs

in

IKKβSSEE

parentheses:

(IKKβ_S177_181E_f,

GAGCTGGATCAGGGCGAACTGTGCACGGAATTTGTGGGGACTCTGC,

and

IKKβ_S177_181E_r,
GCAGAGTCCCCACAAATTCCGTGCACAGTTCGCCCTGATCCAGCTC). Note that
the constitutive activating effect of this mutation of IKKβ has been established previously
6,15

.

Macrophage Culture: Whole marrow was flushed from long bones into α- Minimum
Essential Medium (MEM). Spleens and Fetal livers were crushed into cell suspension in
α-MEM and were centrifuged at 453 rcf. Cell pellets were resuspended in whole media
(α-MEM with 1X penicillin/streptomycin, 10% heat-inactivated fetal bovine serum
(FBS)). Monocytes/ macrophages were produced by growing cell suspensions in the
presence of 10 ng/ml M-CSF. Monocytes/ macrophages were allowed to proliferate for 3
days at 37 oC in 5% CO2 at which point they were infected with retrovirus. See below.

Infection of Macrophages: The use of Plat-E retrovirus packaging cells stably
expressing retroviral structural proteins gag-pol and env for transient production of high
titer retrovirus was described previously 16. Briefly, 8µg pMx vectors expressing our gene of
interest were transfected into 5 million plat-E cells (grown in DMEM supplemented with 10%
FBS, 10ng/ml M-CSF, and penicillin/streptomycin) using Fugene 6 (Roche, Palo Alto, CA)
according to manufacturer’s instructions. Twenty-four hrs post transfection, media was
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exchanged to remove transfection reagent. Twenty-four and 48 hrs post media exchange,
supernatant was collected and pooled. In parallel, monocyte/macrophage cultures from bone
marrow, spleen, or fetal liver were developed on petri dishes, washed with PBS, and infected with
retrovirus in infection mix (50% virus supernatant, 50% αMEM containing 10% FBS, 10ng/ml
M-CSF, penicillin/streptomycin, and 4µg/ml hexadimethrine bromide). Twenty-four hrs post
infection,

cells

were

selected

in

αMEM

containing

10%

FBS,

10ng/ml

M-CSF,

penicillin/streptomycin, and 2µg/ml puromycin for 72 hrs, at which point selection media was
removed, cells were washed, and grown for 24 additional hrs without puromycin. At this point,
cells were lifted, counted, and plated for downstream experiments.

Western Blot: Equivalent amounts of total cell protein were boiled in the presence of an
equal volume of 2X SDS sample buffer consisting of (0.5 M Tris-HCl, pH 6.8, 10%
(w/v) SDS, 10% glycerol, 0.05% (w/v) bromphenol blue, 3% β-Mercaptoethanol (v/v),
and distilled water) for 5 min. and subjected to electrophoresis on 8–10% SDS-PAGE.
Proteins were transferred to nitrocellulose membranes using a semi-dry blotter (Bio-Rad,
Hercules, CA) and incubated in blocking solution (10% skim milk prepared in phosphatebuffered saline containing 0.05% Tween 20) to reduce nonspecific binding. The
membranes were washed with PBS/Tween buffer and exposed to primary antibodies (16
h at 4 oC), washed (4 x 15 min.), and incubated with the appropriate secondary
horseradish peroxidase-conjugated antibodies (1 h at room temperature). The membranes
were washed extensively (4 X 15 min.), and an ECL detection assay was performed
following the manufacturer’s instructions.
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FIGURE LEGENDS

Figure 1. Expression of IKKβSSEE in Monocytes results in RelB Activation
Wild-type monocytes were infected with retroviruses expressing either GFP or flagtagged WT IKKβ or IKKβSSEE for either 0, 1, 2, 4, or 6 days. Nuclear fractions were
separated from cytosolic fractions. Retroviral IKKβ was detected in the cytosolic fraction
by Western blot for flag. RelB was detected in nuclear fraction by Western blot. N,
nuclear. C, cytosolic. ns, non-specific background band.

Figure 2. IKKβSSEE induces p100 processing to p52
Wildtype and NF-κB1/2 double knockout (DKO) monocytes were infected with
retroviruses expressing either GFP or flag-tagged WT IKKβ or IKKβSSEE. Expression of
indicated proteins was detected in total cell lysates by Western Blot. OC+, osteoclast
positive control total cell lysate.

Figure 3. IKKα – independent p52 production by IKKβSSEE
WT and IKKα KO monocytes were infected with retroviruses expressing either GFP or
flag-tagged IKKβSSEE. Expression of the indicated proteins was detected by Western blot.
OC+, osteoclast positive control total cell lysate.
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CHAPTER 6
CONCLUSION
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SUMMARY OF RESULTS

IKKβ is Necessary for Osteoclast Differentiation and Prevents JNK-Mediated
Apoptosis in Differentiating Pre-Osteoclasts
We began with the hypothesis that since NF-κB activity is absolutely critical for
osteoclast differentiation 1, then upstream activators of NF-κB would play an important
role in osteoclastogenesis. We focused on IKKβ to build on previous work in our
laboratory which demonstrated that the NEMO – IKKβ interaction is important for
osteoclast differentiation 2. Further, an osteoclast defect resulting in resistance to
inflammatory osteolysis was noted in mice lacking IKKβ in hematopoietic tissues 3. This
fact, coupled with the observation that IKKα activation is dispensable for
osteoclastogenesis 3 led us to investigate the role IKKβ plays in response to RANKL in
the setting of osteoclastogenesis.

To this end, we used Cre/loxP technology to produce a mouse lacking IKKβ specifically
in osteoclast precursors (OCPs) by crossing mice possessing homozygous floxed IKKβ
alleles

4

with mice transgenically expressing Cre recombinase under the control of the

CD11b promoter 5. Initial observation of Cre-expressing, homozygous floxed IKKβ
(OCPΔIKKβ) mice revealed a defect in bone metabolism, since OCPΔIKKβ demonstrated
shorter and more radio-dense bones on x-ray. Macrophages from these mice isolated
from both spleen and bone marrow showed decreased IKKβ expression at both mRNA
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and protein levels. This confirmed that our genetic targeting of IKKβ in osteoclast
precursors was successful and resulted in defects in bone metabolism.

To determine whether deletion of IKKβ in OCPs affects osteoclast differentiation, we
cultured control and OCPΔIKKβ cells in the presence of M-CSF and RANKL to induce
osteoclast differentiation in vitro. Differentiation of OCPΔIKKβ cells into osteoclasts in
vitro was severely impaired, and long bones of OCPΔIKKβ mice possessed significantly
fewer osteoclasts than control littermates. We demonstrated a defect in RelA nuclear
translocation in response to RANKL in OCPΔIKKβ cells as well, confirming that IKKβ
mediated NF-κB activation in response to RANKL is important for osteoclastogenesis. In
order to determine the cause for impaired osteoclastogenesis in OCPΔIKKβ cells, we
performed quantitative real-time PCR for osteoclast-specific gene expression after
treatment of WT and OCPΔIKKβ cells with M-CSF and RANKL, we noted significantly
reduced induction of osteoclast genes in OCPΔIKKβ cells compared with control cells. This
finding correlated well with our observation that absence of IKKβ results in defective
differentiation of monocytes into osteoclasts. We also determined by real-time PCR that
OCPΔIKKβ cells showed reduced expression of NF-κB-controlled anti-apoptotic proteins.
We hypothesized that perhaps RANKL induced apoptosis of OCPΔIKKβ cells as a result.
Indeed, RANKL treatment of OCPΔIKKβ but not control cells for 4 hrs resulted in PARP
cleavage, an indicator of apoptosis. Furthermore, OCPΔIKKβ mice possessed many
apoptotic osteoclasts associated with bony trabeculae in long bones, suggesting that
osteoclast lineage cells in OCPΔIKKβ mice were susceptible to apoptosis in vivo.
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Analysis of kinase signaling downstream of RANK stimulation in OCPΔIKKβ cells
revealed a gain-of-function of JNK compared with WT cells. Since JNK hyperactivity
has been linked to apoptosis in response to RANKL in differentiating osteoclasts 6, we
hypothesized that inhibition of JNK may rescue the osteoclast defect in OCPΔIKKβ cells.
Indeed, treatment of OCPΔIKKβ monocytes with low doses of a cell-permeable peptide
inhibitor of JNK restored osteoclastogenesis in OCPΔIKKβ. This rescue phenomenon was
only observed with incomplete deletion of IKKβ, whereas OCPs with more efficient
deletion of IKKβ (with less IKKβ mRNA expression) could not be differentiated into
osteoclasts even with JNK inhibition. We concluded that IKKβ serves two functions
which are important for osteoclastogenesis. First, IKKβ inhibits JNK-mediated apoptosis
in response to RANKL. Second, IKKβ facilitates the osteoclast differentiation program
downstream of RANKL.

Constitutive Activation of IKKβ is Sufficient for Osteoclastogenesis
With an established genetic model for deficiency of IKKβ in osteoclast precursors in
hand, our next step was to identify the residues and domains of IKKβ which are
important for its function in the setting of osteoclast differentiation. We took the
approach of retroviral re-introduction of WT IKKβ or mutant forms of IKKβ into
OCPΔIKKβ cells to attempt to rescue osteoclastogenesis. We chose K44M as a negative
control, since this molecule lacks kinase activity 7. Also, in order to test phosphorylation
– dependent loss-of-function and gain-of-function, we tested S177/181A (IKKβSSAA) and
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S177/181E (IKKβSSEE), respectively. Mutation of T-loop Serines to Alanine renders
IKKβ refractory to signal-induced activation, while mutation to Glutamic Acid creates a
constitutively active form of IKKβ 8. In response to RANKL, WT IKKβ restored
osteoclastogenesis

in

OCPΔIKKβ.

IKKβK44M

and

IKKβSSAA

failed

to

rescue

osteoclastogenesis, indicating that RANKL-induced serine phosphorylation of IKKβ is
required for osteoclast differentiation. IKKβSSEE also rescued osteoclastogenesis from
OCPΔIKKβ, and upon closer examination, we made the surprising discovery that IKKβSSEE
induced osteoclast differentiation in the absence of RANKL administration.

This finding led to the hypothesis that phosphorylation of IKKβ at Serines 177 and 181 in
response to RANK stimulation by RANKL represents a molecular switch that activates
the osteoclast differentiation program. Our subsequent investigation was focused on
challenging this hypothesis. First, we characterized the osteoclasts induced by IKKβSSEE
to determine if they met the criteria for authentic osteoclasts derived by RANKL
stimulation of M-CSF-dependent monocytes. Our examination revealed that IKKβSSEE –
induced osteoclasts expressed all markers of mature osteoclasts, formed actin rings, and
resorbed bone. We determined that, indeed, constitutively active IKKβ induces
differentiation of bona fide osteoclasts.

We further demonstrated that IKKβSSEE induced osteoclasts in the absence of the
receptor, RANK, and in the presence of inhibitory concentrations of OPG-fc (which
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interferes with RANKL stimulation of monocytes). These results led us to conclude that
IKKβSSEE induces differentiation of osteoclasts in a RANK – independent manner.

Next, we desired to dissect the molecular environment surrounding IKKβ in the
monocyte. Since IKKβ is a member of the IKK complex 7, and all the members of this
complex play an essential role in osteoclastogenesis 2,9-11, we wondered if the integrity of
the IKK complex was critical for IKKβSSEE to induce osteoclastogenesis. We found that
constitutively active IKKβ could induce osteoclastogenesis in the absence of endogenous
IKKβ and IKKα and in conditions in which NEMO- IKKβ association were inhibited
pharmacologically and genetically. We concluded that IKKβSSEE acts independently and
autonomously with respect to the IKK complex to induce osteoclastogenesis. This result
suggests that the function of the IKK complex downstream of RANKL is to allow for
phosphorylation and activation of IKKβ, which then triggers osteoclast differentiation.

We looked downstream to determine which factors were necessary for IKKβSSEE to
induce RANK-independent osteoclastogenesis. Nuclear/cytosol fractionation experiments
revealed that IKKβSSEE induces nuclear translocation of NF-κB subunits RelA and RelB
and also stimulates increased production of total RelB. Although RelB plays a role in
RANKL-induced osteoclast differentiation

12

, IKKβSSEE induced bone resorbing

osteoclasts from RelB knockout spleen monocytes. Importantly, NF-κB1/NF-κB2 double
knockout macrophages did not become osteoclasts when expressing IKKβSSEE,
demonstrating a pivotal role for NF-κB in this phenomenon. These results suggested that
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constitutive activation of NF-κB by IKKβSSEE is sufficient for RANK-independent
osteoclast differentiation. Overexpression of IKKαSSEE, RelB, or RelA failed to induce
osteoclast differentiation, highlighting the specificity of IKKβ as an inducer of
osteoclastogenesis.

Importantly, kinase activity of IKKβSSEE was critical for mediating its osteoclastogenic
effect, since mutation of Lysine 44 to Methionine in the presence of S177/181E
mutations abrogated the effect. IKKβSSEE demonstrated some qualities which were
surprising. For example, it induced processing of p100 to p52 in monocytes, a function
which is thought to be mediated by IKKα. The role of this phenomenon in inducing
osteoclasts in response to IKKβSSEE is unclear at this point.

We wished to determine whether activation of IKKβ in an in vivo setting possesses
pathological significance. Indeed, adenoviral gene transfer of IKKβSSEE into knees of
mice results in massive inflammation and bone erosion, mimicking the findings in
rheumatoid arthritis.

These data provide evidence that IKKβ is a specific inducer of osteoclast differentiation
and that gain-of-function in IKKβ may contribute to the pathogenesis of inflammatory
osteolysis. Therefore, therapy targeting the activation of IKKβ may represent a successful
approach to ameliorate pathological bone loss.
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Inflammation and Osteoclastogenesis Induced by Constitutively Active IKKβ are
Uncoupled
It is well known that NF-κB is a crucial mediator of osteoclastogenic

1,13

as well as

inflammatory signaling 14-16. Inflammatory inducers such as TNFα and IL-1β have been
shown to contribute to osteoclast differentiation 17,18, so we wondered whether IKKβSSEE
– mediated induction of osteoclastogenesis required these inflammatory modulators. We
demonstrated by quantitative real-time PCR and ELISA that in addition to stimulating
osteoclastogenesis, IKKβSSEE induced expression of the pro-inflammatory cytokines,
TNFα and IL-1β, by monocytes. Since these two cytokines have been shown to induce
RANK-independent osteoclast differentiation from monocytes in the presence of TGF-β
19

, we wondered if TNFα and IL-1β were responsible for inducing osteoclast

differentiation in our system. We demonstrated in TNFα knockout and IL-1 receptor
knockout monocytes that IKKβSSEE was still capable of inducing osteoclast
differentiation in vitro. Whether the inflammatory component downstream of IKKβSSEE
plays a role in the arthritis pathogenesis in the adenoviral IKKβSSEE in vivo model is still
to be investigated, but it is absolutely clear that constitutively active IKKβ can drive
osteoclastogenesis in a cell-autonomous, NF-κB-dependent, inflammatory cytokineindependent manner.

Altogether, our work has identified IKKβ as a central regulator of the osteoclast program.
It is essential for normal differentiation of osteoclasts in response to RANKL, and gainof-function results in spontaneous osteoclast formation in the absence of RANKL. It is
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likely that IKKβ gain-of-function – whether mutational or signal-induced - plays a role in
osteolysis in patients with inflammatory diseases, and our work leads us to strongly
support targeting of IKKβ for amelioration of these conditions.

FUTURE DIRECTIONS

Screening Patients with Inflammatory Bone Loss for IKKβ Gain-of-Function
Mutations
Our results strongly suggest that gain-of-function in IKKβ results in spontaneous
osteoclastogenesis that occurs in the absence of upstream signals. Since IKKβ is an
essential downstream component in RANKL-induced osteoclast differentiation

10

, and

since gain-of-function in the RANKL/RANK pathway results in pathological conditions
of heightened bone turnover

20,21

, it is likely that gain-of-function mutations in IKKβ

could cause osteolysis in human patients. Currently, genetic diagnosis of many of these
conditions remains elusive

22,23

. A diagnostic approach which involves screening for

IKKβ mutations may lend insight into the pathogenesis of these and other inflammatory
conditions involving heightened bone turnover.

Identification of Substrates of IKKβ Important in Osteoclastogenesis
IKKβ has recently been shown to phosphorylate several proteins in addition to its
canonical target, IκBα

24

. When we overexpressed p65/RelA in monocytes, mimicking

the outcome of phosphorylation-dependent degradation of IκBα, we did not observe
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induction

of

osteoclastogenesis.

However,

given

that

IKKβSSEE

induces

osteoclastogenesis in a kinase-dependent manner, it is likely that there are additional
targets of IKKβ in the monocyte which mediate this effect. We propose a high-power
approach to screen multiple targets of IKKβSSEE with the use of phosphoprotein detection
by mass spectrometry

25

. Identification of these molecules will lead to a better

understanding of the mechanisms through which IKKβ activates the osteoclast program.
Furthermore, identification of these molecules will lend insight into potential modes of
therapy for inflammatory conditions.

Structure Function Analysis of IKKβ for Therapeutic Peptide Design
We have demonstrated that constitutively active IKKβ is an extremely specific inducer of
osteoclast differentiation. Constitutively active IKKα, although possessing more than
50% sequence conservation with IKKβ 7, fails to induce osteoclastogenesis. We
rationalize that we can take advantage of the differences between IKKβ and IKKα in
order to learn which unique regions in IKKβ confer its osteoclast – inducing properties.
This can be accomplished through domain swapping by PCR to generate chimeric
molecules. Also, structurally unique regions in IKKβ can be sequentially mutated to
determine the minimum essential structure which preserves IKKβ function. Important
regions may be further investigated biochemically to determine how they regulate IKKβ
activity, and they can be targeted or mimicked molecularly to interfere with IKKβ
function. This approach will lead to novel therapeutic modalities in inflammatory
diseases.
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Amelioration of Osteopetrosis
Osteopetrosis is a condition of dense brittle bone owing mostly to defective osteoclast
function or differentiation

26

. Most forms of clinical and experimental osteopetrosis are

amenable to bone marrow transplantation, which means that correction of a defect in the
hematopoietic compartment rescues the osteoclast defect. We have identified a potential
approach using viral gene transfer of constitutively active IKKβ to correct an osteoclast
differentiation defect in cells. Theoretically, using this approach, osteoclast precursors
from an osteopetrotic mouse or congenic mouse, and perhaps a patient whose
osteopetrosis results from defective osteoclast differentiation, may be infected with a
virus expressing active IKKβ and then reintroduced locally into bone. IKKβ would
trigger osteoclast differentiation in progenitors and would correct the osteopetrosis. There
are potential pitfalls of this approach related to NF-κB-mediated inflammation.
Nevertheless, exploring new means to cure this disease may prove to be therapeutically
beneficial in the future.
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PERSPECTIVES

Given the wide range of pathological conditions in which NF-κB activity is believed to
play a role, an intense effort to develop drugs which target the NF-κB signaling pathway
is logical and justified. Our data provide evidence that these drugs may prove to be
beneficial in reducing bone – destructive effects of inflammatory conditions. Exciting
progress has been made toward discovery of selective small-molecule inhibitors of IKKβ,
which are now in the pre-clinical phase of testing 27. Given the central role for IKKβ in
differentiation of the osteoclast, the continued effort to target this molecule provides hope
for effective therapy in patients with conditions of inflammatory osteolysis and other
conditions of pathologically heightened bone turnover.
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